<!DOCTYPE html>

<html lang="en">
<!--[325954|cccs|]--><head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Tecfidera: Side effects, dosage, uses, and more</title>
<meta property='og:url' content='https://www.medicalnewstoday.com/articles/325954.php'/>		<meta property="og:type" content="article"/>
		<meta property="og:site_name" content="Medical News Today"/>
		<meta property="og:title" content="Tecfidera: Side effects, dosage, uses, and more"/>
					<meta property="og:description" content="Tecfidera (dimethyl fumarate) is a brand-name prescription drug that's used to treat relapsing forms of multiple sclerosis (MS). It's classified as a disease-modifying therapy. Tecfidera comes as a delayed-release oral capsule. It doesn't have a generic version. Learn about side effects, warnings, dosage, and more."/>
			<meta name="description" content="Tecfidera (dimethyl fumarate) is a brand-name prescription drug that's used to treat relapsing forms of multiple sclerosis (MS). It's classified as a disease-modifying therapy. Tecfidera comes as a delayed-release oral capsule. It doesn't have a generic version. Learn about side effects, warnings, dosage, and more."/>
						<meta property="og:image" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
					<meta property="fb:admins" content="1658973110"/>
		<meta property="fb:app_id" content="147184211975697"/>
					<meta itemprop="description" content="Tecfidera (dimethyl fumarate) is a brand-name prescription drug that's used to treat relapsing forms of multiple sclerosis (MS). It's classified as a disease-modifying therapy. Tecfidera comes as a delayed-release oral capsule. It doesn't have a generic version. Learn about side effects, warnings, dosage, and more."/>
						<meta itemprop="image" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
					<meta name="twitter:domain" content="medicalnewstoday.com"/>
		<meta name="twitter:card" content="summary_large_image"/>
		<meta name="twitter:site" content="@mnt"/>
		<meta name="twitter:title" content="Tecfidera: Side effects, dosage, uses, and more"/>
					<meta name="twitter:description" content="Tecfidera (dimethyl fumarate) is a brand-name prescription drug that's used to treat relapsing forms of multiple sclerosis (MS). It's classified as a disease-modifying therapy. Tecfidera comes as a delayed-release oral capsule. It doesn't have a generic version. Learn about side effects, warnings, dosage, and more."/>
					<meta name="twitter:creator" content="@mnt"/>
					<meta name="twitter:image:src" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
			<META name="rating" content="general">
<META http-equiv="Cache-Control" content="no-cache">
<meta name="p:domain_verify" content="ca332f19ebf583ba72eff99cc210a982"/>
<meta name="msvalidate.01" content="65DAC77377665AE872AC660E37807BC6" />
<META http-equiv="bulletin-text" content="Copyright">

			<link rel="canonical" href="https://www.medicalnewstoday.com/articles/325954.php">
			
<link rel="shortcut icon" type="image/png" href="https://cdn-prod.medicalnewstoday.com/favicon.png">
<link rel="icon" sizes="32x32" href="https://cdn-prod.medicalnewstoday.com/favicon.ico">
<link rel="apple-touch-icon" type="image/png" href="https://cdn-prod.medicalnewstoday.com/apple-touch-icon.png">

	<link rel="alternate" type="application/rss+xml" title="Medical News Today - Health News Headlines RSS Feed" href="https://rss.medicalnewstoday.com/featurednews.xml">
	<link rel="alternate" type="application/json" title="Medical News Today - Health News Headlines JSON Feed" href="https://rss.medicalnewstoday.com/json/featurednews.json">
	
<meta http-equiv="x-dns-prefetch-control" content="on">
<link rel="preconnect dns-prefetch" href="//cdn-prod.medicalnewstoday.com" crossorigin>
<link rel="preconnect dns-prefetch" href="//cdn2.medicalnewstoday.com" crossorigin>


	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff2">
	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-Light.woff2">
	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-Regular.woff2">


	<style>
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff') format('woff');
			font-weight:900;
			font-display: swap;}
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-Light.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-Light.woff') format('woff');
			font-weight:200;
			font-style:lighter;
			font-display: swap;}
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-Regular.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-Regular.woff') format('woff');
			font-weight:400;
			font-weight:normal;
			font-style:normal;
			font-display: swap;}

		@font-face {
			font-family: 'ProximaNova';
			src: url('https://cdn-prod.medicalnewstoday.com/structure/fonts/ProximaNova/ProximaNova-Bold.woff2') format('woff2'),
			url('https://cdn-prod.medicalnewstoday.com/structure/fonts/ProximaNova/ProximaNova-Bold.woff') format('woff');
			font-weight:600;
			font-weight:bold;
			font-style:bold;
			font-display: swap;}

		@font-face {
			font-family: 'Arnhem';
			src: url('https://cdn-prod.medicalnewstoday.com/structure/fonts/Arnhem/ArnhemPro-Bold.woff') format('woff');
			font-weight:600;
			font-weight:bold;
			font-style:bold;
			font-display: swap;}
	</style>





	
<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" rel="stylesheet" integrity="sha384-wvfXpqpZZVQGK6TAh5PVlGOfQNHSoD2xbE+QkPxCAFlNEevoEH3Sl0sibVcOQVnN" crossorigin="anonymous">

					<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_default_redesign_7721.css?v=190904" type="text/css" media="all" />
		

		



					<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_print_redesign_7721.css?v=20181203" type="text/css" media="print">
				
		


<!--[if lt IE 9]>
<script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>

			<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_ie.css" type="text/css" media="all" />
	


	<![endif]-->
<!--[if IE 7]>

<script src="//ie7-js.googlecode.com/svn/version/2.1(beta4)/IE7.js"></script>
<![endif]-->	
<!--[if IE 9]>
<script src="//ie7-js.googlecode.com/svn/version/2.1(beta4)/IE9.js"></script>
<![endif]-->


<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=0.2, maximum-scale=2.0, user-scalable=1"><!--desktop-->


<noscript>
<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/styles_noscript.css" type="text/css" media="all" />	
</noscript>
<script type="text/javascript" >
			var glob_mntcookie = 1;
	  </script>
<script>

glob_JS=(typeof glob_JS === 'undefined')?{'GAInit':[],'GA':[],"ExternalJS":[],"AD":[]}:glob_JS;

glob_TrueOnGDPR=(glob_mntcookie!=1);

//if use GDPR is true, we need this flag to make sure ga queue can ber execute after ga is ready
glob_isGaReady=!glob_TrueOnGDPR;



if(typeof fireOrSaveGoogleAdFunctions === 'undefined'){



    function fireOrSaveGoogleAdFunctions(adFunction){

        if(!glob_TrueOnGDPR){

            adFunction();

        }else{

            if(typeof fireOrSaveGoogleADs === 'undefined'){
                //save ad event in queue
                glob_JS.AD.push(adFunction);
            }else{
                //let next function to determine save or fire ad function
                fireOrSaveGoogleADs(adFunction);

            }
        }

    }

    function fireOrSaveJsFunctions(jsType,jsFunction){

        if(!glob_TrueOnGDPR && jsType!=0){
            //if GDPR already accept, and func type is not ga event, just exec

            jsFunction()

        }else if(!glob_TrueOnGDPR && jsType===0) {
            //for ga event only

            if(glob_isGaReady) {
                //if ga ready, call the function
                jsFunction();
            }else{
                //if user accept GDPR, but ga not ready, still push new command into queue
                glob_JS.GA.push(jsFunction);

            }

        }else{

                if(jsType<0){
                    jsType='GAInit'
                }else if(jsType==0){
                    jsType='GA';
                }else{
                    jsType='ExternalJS';
                }

                if(typeof fireJS === 'undefined'){
                    //save ad event in queue


                    if(jsType=='GAInit'){

                        glob_JS.GAInit.push(jsFunction);

                    }else if(jsType=='GA') {

                        glob_JS.GA.push(jsFunction);
                    }else
                    {
                        //default is other js
                        glob_JS.ExternalJS.push(jsFunction);
                    }


                }else{
                    //let next function to determine save or fire ad function
                    fireJS(jsType,jsFunction);

                }
            }
    }



    function loadScript(url, parameters,callback){



        var script = document.createElement("script");
        script.type = "text/javascript";


        //add custom attribute
        for (var key in parameters) {
            if (parameters.hasOwnProperty(key)) {
                script.setAttribute(key,parameters[key]);
            }
        }


        if (script.readyState){  //IE
            script.onreadystatechange = function(){
                if (script.readyState == "loaded" ||
                    script.readyState == "complete"){
                    script.onreadystatechange = null;
                    callback();
                }
            };
        } else {  //Others
            script.onload = function(){

                if(typeof callback === 'function'){
                    callback();
                }

            };
        }

        script.src = url;
        document.getElementsByTagName("head")[0].appendChild(script);
    }



}

</script>




<!--<script type='text/javascript'>
(function() {
var useSSL = 'https:' == document.location.protocol;
var src = (useSSL ? 'https:' : 'http:') +
'//www.googletagservices.com/tag/js/gpt.js';
document.write('<scr' + 'ipt src="' + src + '"></scr' + 'ipt>');
})();
</script>-->


<script type="text/javascript">
	//CMP	
 	var isEEA = false;
 	var passEEACheck = false;

	var metadata = 'BOSk20WOSk20WABABBENBR-AAAAeCAFAAUABwAEAANABCA';
	var purposeConsents = { 1: true, 2: true, 3: true, 4: true, 5: true };
	var vendorConsents = { 10:true, 28: true, 32: true, 52: true, 132: true };

		function __cmp(cmd, p, cb) {
			if (cmd === 'getVendorConsents' || cmd === 'getConsentData') {
				cb({
					hasGlobalScope: true,
					gdprApplies: isEEA,
					metadata: metadata,
					consentData: metadata,
					purposeConsents: purposeConsents,
					vendorConsents: vendorConsents
				}, true);
			} else if (cmd === 'ping') {
				cb({gdprAppliesGlobally: false, cmpLoaded: isEEA});
			} else {
				throw new Error('Invalid CMP command '+ cmd);
			}
		}
</script>
<!-- <script async src="//js-sec.indexww.com/ht/p/184901-208206248649346.js"></script> -->
<!-- <script async src="//js-sec.indexww.com/ht/p/180447-192872210293780.js"></script> -->
<script type="text/javascript">
	fireOrSaveJsFunctions(1,function(){
		(function() {
			var indexWrapper = document.createElement("script");
			indexWrapper.async = true;
			indexWrapper.type = "text/javascript";
			var useSSL = "https:" == document.location.protocol;
			indexWrapper.src = (useSSL ? "https:" : "http:") + "//js-sec.indexww.com/ht/p/180447-192872210293780.js";
			var node =document.getElementsByTagName("script")[0];
			node.parentNode.insertBefore(indexWrapper, node);
		})();
	});
</script>
<script type="text/javascript">
fireOrSaveJsFunctions(1,function(){
	window.headertag = window.headertag || {};
	window.headertag.pagetype='drugs';
});
</script>

<script type="text/javascript">
	//ADBRIDG MIGRATION: Load the Adbridg library directly after the GPT library. 
  var AdBridg = AdBridg || {};
  AdBridg.cmd = AdBridg.cmd || [];
  window.adbridgFallback = function() {
		console.log('ADBRIDG MIGRATION: library failed to load; falling back to GPT');
    var dq = [], l = [], ls = {}, lf = [], es;
    var rl = function(f) {return function(){var a=arguments, x=function(){f.apply(null,a)};lf.push(x);pl()}}
    var pl = function() {if(!l.length){while(lf.length){(lf.shift())()}}}
    dq.process = function() { while(dq.length) { googletag.display(dq.shift()); }}
    AdBridg.defineSlot = function(p, s, d) { return googletag.defineSlot(p, s, d).addService(googletag.pubads()); }
    AdBridg.defineOutOfPageSlot = function(p, d) { return googletag.defineOutOfPageSlot(p, d).addService(googletag.pubads()); }
    AdBridg.destroySlots = function(s) { return googletag.destroySlots(s); }
    AdBridg.display = function(d) { dq.push(d); if (es) { dq.process(); }}
    AdBridg.refresh = function(s, o) { googletag.pubads().refresh(s, o); }
    AdBridg.render = function() { }
    AdBridg.serve = function() { googletag.enableServices(); es=1; dq.process(); }
    AdBridg.sizeMapping = function() { return googletag.sizeMapping(); }
    AdBridg.useSizeMapping = function() { }
    AdBridg.lock = function(s) {if(ls[s]){ls[s]=null;return;}l.push(s);pl()}
    AdBridg.unlock = function(s) {var f=0; for(var i=0;i<l.length;++i){if(l[i]==s){l.splice(i,1);f=1}}; if(!f){ls[s]=1} pl()}
		AdBridg.cmd.push = function(f) {
			if (typeof(f)=='object') {
				var api_fallback = function(o) {
					googletag.cmd.push(function() {
						var fl;
						if (o.gpt_path) {
							var u=AdBridg.defineSlot(o.gpt_path,o.size||[],o.dom_id);
							if(o.size_map) {
								var m = googletag.sizeMapping();
								for(var oi=0;oi<o.size_map.length;oi++){m=m.addSize(o.size_map[oi].viewport, o.size_map[oi].sizes);}
								u.defineSizeMapping(m.build());
							}
							if(o.events) {
								if(o.events["gpt.defined"]){o.events["gpt.defined"](u);}
								fl = function(a,b){if(o.events[a]){googletag.pubads().addEventListener(b,function(e){if(e.slot===u){o.events[a](u,e)}})}}
								fl("gpt.rendered",'slotRenderEnded');
								fl("gpt.viewed",'impressionViewable');
								fl("gpt.visibilityChanged",'slotVisibilityChanged');
							}
						} else if (o.events) {
							fl = function(a,b){if(o.events[a]){googletag.pubads().addEventListener(b,function(e){o.events[a](a,e)})}}
							fl("gpt.render_raw",'slotRenderEnded');
							fl("gpt.viewed_raw",'impressionViewable');
						}
					});
				}
				if(f.length){for(var i=0;i<f.length;++i){api_fallback(f[i]);}}else{api_fallback(f);}
				f=function(){AdBridg.serve()}
			}
			return googletag.cmd.push(f);
		}
		while (AdBridg.cmd.length) { AdBridg.cmd.push(AdBridg.cmd.shift()); }
  };
	fireOrSaveJsFunctions(1, function() {
		(function() {
	      var adb = document.createElement("script");
	      adb.async = true;
	      adb.type = "text/javascript";
	      adb.src = '//prod.adspsp.com/adb.2418030m.min.js';
	      var node = document.getElementsByTagName('script')[0];
	      node.parentNode.insertBefore(adb, node);

	      // Return control to GPT if the AdBridg library fails to load.
	      adb.onerror = function() {
	        if (AdBridg.exists) { return; }
	        document.createElement('IMG').src = '//adspsp.com/pt/2418030/3/1/?e=0';
	        window.adbridgFallback();
	      }
	  })();
	});
</script>

<!-- Load DFP -->
<script type="text/javascript">
	var googletag = googletag || { };
	googletag.cmd = googletag.cmd || [ ];
	fireOrSaveJsFunctions(1,function(){
		(function() {
			var gads = document.createElement("script");
			gads.async = true;
			gads.type = "text/javascript";
			var useSSL = "https:" == document.location.protocol;
			gads.src = (useSSL ? "https:" : "http:") + "//www.googletagservices.com/tag/js/gpt.js";
			var node =document.getElementsByTagName("script")[0];
			node.parentNode.insertBefore(gads, node);
		})();
	});
</script>

<!--New header bidding-->
<script>
var amzn_win=window,amzn_c=5,amzn_x=0;while(amzn_x<amzn_c){amzn_win=amzn_win.parent;if(amzn_win.apstag)try{amzn_win.apstag.renderImp(document,"%%PATTERN:amzniid%%");amzn_x=amzn_c}catch(e){}amzn_x++};
</script> 

<script type="text/javascript">
	fireOrSaveGoogleAdFunctions(function() {
		AdBridg.cmd.push(function () {
			// ADBRIDG MIGRATION: this command to set AdSense is one of the few
			// GPT commands that should not be replaced with our library proxy.
			googletag.pubads().set("adsense_background_color", "FFFFFF");
		});
	});
</script>


<script type="text/javascript">
	var googleDegfaultAdVars = {"main":"'multiple_sclerosis'","sub":"'pharmacy'","k1":"'ms'","k2":"'musculoskeletal'","k3":"'health'","uniq":"'325954'","msiteID":"'tecfideracdi'","msiteactive":"'True'","sponsoredPageNid":"''"};
	var googleAdSlotInfo = [];
	
	fireOrSaveGoogleAdFunctions(function(){
		AdBridg.cmd.push({
		  config: {
		    k1: googleDegfaultAdVars.k1 || "",
		    k2: googleDegfaultAdVars.k2 || ""
		  }
		});	
	});
	
</script>

<!-- End of old ads area -->
<script type='text/javascript'>
//Page level targeting setup
var adRPV = Math.floor(Math.random()*100)+1;
adRPV = adRPV.toString();

fireOrSaveGoogleAdFunctions(function(){
// ADBRIDG MIGRATION: the `cmd` function needs to run through AdBridg, but the
// setTargeting methods should stay native to GPT.
AdBridg.cmd.push(function() {
	googletag.pubads().setTargeting('rpv', adRPV);
	//We need to add a new key for 'url'
    googletag.pubads().setTargeting('url', encodeURI(location.pathname));

    //Set default targeting first
            if (typeof googleDegfaultAdVars !== "undefined") {
            for (var k in googleDegfaultAdVars) {
                if (k == "sub" || googleDegfaultAdVars[k].toString().indexOf(",") > -1) {
                    var finalOutput = googleDegfaultAdVars[k].split(',');
                    //Remove the single qoute
                    for (var i in finalOutput) {
                        if (finalOutput[i].trim().toString().indexOf("'") == 0) {
                            finalOutput[i] = finalOutput[i].trim().slice(1, -1);
                        } else {
    						finalOutput[i] = finalOutput[i].trim();
                        }
                    }
                } else {
                    if (googleDegfaultAdVars[k].toString().indexOf("'") == 0) {
                        //if it got single qoute inside, we remove it
                        var finalOutput = googleDegfaultAdVars[k].slice(1, -1);
                    } else {
                        var finalOutput = googleDegfaultAdVars[k];
                    }
                }
                googletag.pubads().setTargeting(k, finalOutput);
            }
        }
    	//googletag.pubads().enableAsyncRendering(); // enable async loading
	// Disable initial load, we will use refresh() to fetch ads.
	// Calling this function means that display() calls just
	// register the slot as ready, but do not fetch ads for it.
	// googletag.pubads().disableInitialLoad();
 //  	googletag.pubads().enableSingleRequest();
    // googletag.pubads().enableLazyLoad({
    //     fetchMarginPercent: 50,  // Fetch slots within 5 viewports.
    //     renderMarginPercent: 30,  // Render slots within 2 viewports.
    //     mobileScaling: 2.0  // Double the above values on mobile.
    // });
	// googletag.enableServices();
    // ADBRIDG MIGRATION: by default, we enable single request, disable initial
    // load, and async rendering is enabled by default (GPT no longer supports
    // synchronous rendering as of 2019-01-21.)
    // All we need to do now is tell AdBridg to begin serving the ads.
    // AdBridg.serve();
    // console.log("serve happened in page level");

});
});
</script>
<script>
// check viewport for resize events and reload ads (1000ms delay)
var resizeTimer;
var width = window.innerWidth;

function resizer() {
	//Check to see if the width is changed 
	var newWidth = window.innerWidth;
	if (width != newWidth) {
		// check if we've crossed a break point (only need to refresh if crossing the 1000px break point)
		if (width >= 1000 && newWidth < 1000) {
			
							// DECREASE IN WIDTH
				fireOrSaveGoogleAdFunctions(function() {
					AdBridg.cmd.push(function () {
						if (typeof window.DLB1 !== "undefined") {
							AdBridg.refresh([window.DLB1]);
						}
					});
				});
			
			// send resize+refresh event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / Shrink / Ad refresh', eventLabel: 'Resize / Shrink / Ad refresh'});});
			
		} else if (width < 1000 && newWidth >= 1000) {
			
			// INCREASE IN WIDTH
			// 
							if(typeof window.DLB1 !== "undefined"){
					AdBridg.refresh([window.DLB1]);	
				}
						
			// send resize+refresh event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / Grow / Ad refresh', eventLabel: 'Resize / Grow / Ad refresh'});});
			
		} else {
			// send resize event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / No ad refresh', eventLabel: 'Resize / No ad refresh'});});
		}
	}

	width = newWidth;
}

window.addEventListener("resize", function(){ 
	clearTimeout(resizeTimer);
	resizeTimer = setTimeout(resizer, 1000);
});

</script>

<!--New header bidding-->
<script>
		!function(a9,a,p,s,t,A,g){if(a[a9])return;function q(c,r){a[a9]._Q.push([c,r])}a[a9]={init:function(){q("i",arguments)},fetchBids:function(){q("f",arguments)},setDisplayBids:function(){},_Q:[]};A=p.createElement(s);A.async=!0;A.src=t;g=p.getElementsByTagName(s)[0];g.parentNode.insertBefore(A,g)}("apstag",window,document,"script","//c.amazon-adsystem.com/aax2/apstag.js");


		var initParams = {
			pubID: '3083',
			adServer: 'googletag'
		};


		fireOrSaveJsFunctions(1,function(){

			if (passEEACheck||(isEEA&&glob_mntcookie)) {
				__cmp('getConsentData', null, function(vendorConsentData, success) {
					
					initParams.gdpr = { enabled: true, consent: vendorConsentData.metadata };
					apstag.init(initParams);
				});
			} else {
				apstag.init(initParams);
			}

	 })

</script>

	


	<script type="text/javascript">
	this.top.location!==this.location&&(this.top.location=this.location);
	</script>
	<style>.async-hide { opacity: 0 !important} </style>
<script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date;
h.end=i=function(){s.className=s.className.replace(RegExp(' ?'+y),'')};
(a[n]=a[n]||[]).hide=h;setTimeout(function(){i();h.end=null},c);h.timeout=c;
})(window,document.documentElement,'async-hide','dataLayer',4000,
{'GTM-W59HFNJ':true});</script>

	<script type="text/javascript">

			<!-- GA Universal Code 2014-08 (obfuscated) -->

			eval(function(p,a,c,k,e,d){e=function(c){return(c<a?'':e(parseInt(c/a)))+((c=c%a)>35?String.fromCharCode(c+29):c.toString(36))};while(c--){if(k[c]){p=p.replace(new RegExp('\\b'+e(c)+'\\b','g'),k[c])}}return p}('5(-1,2(){(2(i,s,o,g,r,a,m){i[\'c\']=r;i[r]=i[r]||2(){(i[r].q=i[r].q||[]).e(d)},i[r].l=1*j h();a=s.b(o),m=s.6(o)[0];a.7=1;a.8=g;m.9.k(a,m)})(y,A,\'z\',\'//x.n-3.t/3.u\',\'4\')});5(-1,2(){4(\'v\',\'p-w-1\',\'f\')});',37,37,'||function|analytics|ga|fireOrSaveJsFunctions|getElementsByTagName|async|src|parentNode||createElement|GoogleAnalyticsObject|arguments|push|auto||Date||new|insertBefore|||google||UA||||com|js|create|849615|www|window|script|document'.split('|')))


	</script>
		<script type="text/javascript">
	/*
	CSS Browser Selector v0.4.0 (Nov 02, 2010)
	Rafael Lima (http://rafael.adm.br)
	http://rafael.adm.br/css_browser_selector
	License: http://creativecommons.org/licenses/by/2.5/
	Contributors: http://rafael.adm.br/css_browser_selector#contributors
	*/
	function css_browser_selector(u){var ua=u.toLowerCase(),is=function(t){return ua.indexOf(t)>-1},g='gecko',w='webkit',s='safari',o='opera',m='mobile',h=document.documentElement,b=[(!(/opera|webtv/i.test(ua))&&/msie\s(\d)/.test(ua))?('ie ie'+RegExp.$1):is('firefox/2')?g+' ff2':is('firefox/3.5')?g+' ff3 ff3_5':is('firefox/3.6')?g+' ff3 ff3_6':is('firefox/3')?g+' ff3':is('gecko/')?g:is('opera')?o+(/version\/(\d+)/.test(ua)?' '+o+RegExp.$1:(/opera(\s|\/)(\d+)/.test(ua)?' '+o+RegExp.$2:'')):is('konqueror')?'konqueror':is('blackberry')?m+' blackberry':is('android')?m+' android':is('chrome')?w+' chrome':is('iron')?w+' iron':is('applewebkit/')?w+' '+s+(/version\/(\d+)/.test(ua)?' '+s+RegExp.$1:''):is('mozilla/')?g:'',is('j2me')?m+' j2me':is('iphone')?m+' iphone':is('ipod')?m+' ipod':is('ipad')?m+' ipad':is('mac')?'mac':is('darwin')?'mac':is('webtv')?'webtv':is('win')?'win'+(is('windows nt 6.0')?' vista':''):is('freebsd')?'freebsd':(is('x11')||is('linux'))?'linux':'','js']; c = b.join(' '); h.className += ' '+c; return c;}; css_browser_selector(navigator.userAgent);
	</script>
	<script type="text/javascript">
var viewportWidth = Math.max(document.documentElement.clientWidth, window.innerWidth || 0);
var viewportHeight = Math.max(document.documentElement.clientHeight, window.innerHeight || 0);

	switch (true) {
		case viewportWidth > 1360:
			var viewportBreakpoint = 'Desktop - XL';
			break;
		case viewportWidth > 1200:
			var viewportBreakpoint = 'Desktop - L';
			break;
		case viewportWidth > 1000:
			var viewportBreakpoint = 'Desktop - M';
			break;
		default:
			var viewportBreakpoint = 'Desktop - S';
	}
	
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension20', viewportBreakpoint);});

var existUserId=false;
var vanillaAjax=function(url,httpMethod,data,headerJsonString){

	var request = new XMLHttpRequest();


	request.open(httpMethod, url, true);


	//set header if exist
	try{
		var headerObj=JSON.parse(headerJsonString);

		for (var headerName in headerObj) {

			//optional check for properties from prototype chain
			if (headerObj.hasOwnProperty(headerName)) {
				//no a property from prototype chain

				var headerValue = headerObj[headerName];
				request.setRequestHeader(headerName,headerValue);

			}
		}

	}catch(e){
		console.log("Set datadog api header failed");
		//don't set header if something wrong;
	}




	request.onload = function() {

		if (request.status >= 200 && request.status < 400) {
			// Success!
			var resp = request.responseText;

		} else {
			// We reached our target server, but it returned an error

		}
	};

	request.onerror = function() {
		// There was a connection error of some sort
	};

	request.send(data);

};



function getUrlVars(targetField) {
	var vars = {};
	var parts = window.location.href.replace(/[?&]+([^=&]+)=([^&]*)/gi,
	function(m,key,value) {
		vars[key] = value;
	});

	if(typeof vars[targetField] !== "undefined"){

		return vars[targetField];

	}else{

		return "";
 	}

}


fireOrSaveJsFunctions(0,function() {ga('set', 'dimension35', getUrlVars("tc"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension36', getUrlVars("subid"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension37', getUrlVars("subid2"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension38', getUrlVars("apsid"));});


//set dimension34 value if exist

if(existUserId){

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension34', existUserId);});

}else if(getUrlVars("apid")){

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension34', getUrlVars("apid"));});

	vanillaAjax("/account/message-session-setter.php","POST","activation_platform_user_id="+getUrlVars("apid"),"{\"Content-type\":\"application/x-www-form-urlencoded\"}");

}

//will be called from newsletter register.
function setUserId(userId){

ga('set', 'dimension34', ""+userId);

}

fireOrSaveJsFunctions(0,function() {ga('set', 'dimension40', 'Lindsay Slowiczek, PharmD');});
		

fireOrSaveJsFunctions(0,function() {ga('set', {
'dimension1': "no",
'dimension2': "drugs_tabbed",
'dimension3': "Multiple Sclerosis",
'dimension5': "week",
'dimension6': "desktop",
'dimension12': "2019-08-31",
'dimension17': "7721",
'dimension21': "2",
'dimension23': "MNT’s Medical Network",
'dimension24': "Pharmacy / Pharmacist",
'dimension27': "1",
'dimension28': "ms",
'dimension29': "musculoskeletal"
});});

if (window.devicePixelRatio) {
	var pixelRatio = (window.devicePixelRatio >= 1.5) ? "HiDPI" : "1X";
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension7', pixelRatio);});
}

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension10', viewportWidth);});
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension11', viewportHeight);});
	
	var MNT_ga_paramKey = (document.location.search.indexOf('?') > -1 ? '&' : '?');
	var MNT_ga_url_msId_fragment = MNT_ga_paramKey + 'gaPage=[tecfideracdi]';  
	var MNT_ga_url_msId = document.location.pathname + document.location.search + MNT_ga_url_msId_fragment;
	
		fireOrSaveJsFunctions(0,function() {ga('set', 'page', MNT_ga_url_msId);});
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension16', 'tecfideracdi');});fireOrSaveJsFunctions(0,function() {ga('require', 'GTM-W59HFNJ');});
fireOrSaveJsFunctions(0,function() {ga('send', 'pageview');});

setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 030','325954')});",30000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 050','325954')});",50000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 070','325954')});",70000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 090','325954')});",90000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 110','325954')});",110000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 130','325954')});",130000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 150','325954')});",150000)
</script>
<script>
	fireOrSaveJsFunctions(1,function() {

		var _qevents = _qevents || [];

		(function() {
			var elem = document.createElement('script');
			//elem.src = (document.location.protocol == "https:" ? "https://secure" : "http://edge") + ".quantserve.com/quant.js";
			elem.src = "https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/quant.js";
			elem.async = true;
			elem.type = "text/javascript";
			var scpt = document.getElementsByTagName('script')[0];
			scpt.parentNode.insertBefore(elem, scpt);
		})();

		_qevents.push({
			qacct:"p-v03RmX3GES6RT"
		});
	});


</script>

<script>
	fireOrSaveJsFunctions(1,function() {

		window._comscore = window._comscore || [];
		window._comscore.push({ c1: "2", c2: "19983957" });
		(function() {
			var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
			//s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
			s.src = "https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/beacon.js";
			el.parentNode.insertBefore(s, el);
		})();

	})

</script>
<noscript>
  <img class="no_js" src="https://sb.scorecardresearch.com/p?c1=2&c2=19983957&cv=2.0&cj=1" />
</noscript>

<script>


	fireOrSaveJsFunctions(1,function() {

		!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
			n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
			n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
			t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
			document,'script','https://connect.facebook.net/en_US/fbevents.js');

		fbq('init', '1039134266174910');
		fbq('track', "PageView");

		fbq('track', 'ViewContent');

	});


</script>

<noscript><img height="1" width="1" style="display:none"
src="https://www.facebook.com/tr?id=1039134266174910&ev=PageView&noscript=1"
/></noscript>

<!-- Source: /controltag?confid=qqeynsltk&site=medical%20news%20today&edit=1 -->
<script class="kxct" data-id="qqeynsltk" data-timing="async" data-version="1.9" type="text/javascript">
	fireOrSaveJsFunctions(1,function() {
		window.Krux || ((Krux = function () {
			Krux.q.push(arguments)
		}).q = []);
		(function () {
			var k = document.createElement('script');
			k.type = 'text/javascript';
			k.async = true;
			var m, src = (m = location.href.match(/\bkxsrc=([^&]+)/)) && decodeURIComponent(m[1]);
			k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" :
			(location.protocol === "https:" ? "https:" : "http:") + "//cdn.krxd.net/controltag?confid=qqeynsltk";
			var s = document.getElementsByTagName('script')[0];
			s.parentNode.insertBefore(k, s);
		}());
	});
</script>


<!-- Hotjar Tracking Code for https://www.medicalnewstoday.com/ -->
<script>
	(function(h,o,t,j,a,r){
		h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
		h._hjSettings={hjid:1295463,hjsv:6};
		a=o.getElementsByTagName('head')[0];
		r=o.createElement('script');r.async=1;
		r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
		a.appendChild(r);
	})(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
</script>
<script type="text/javascript"> window.jstag=function(){function t(t){return function(){return t.apply(this,arguments),this}}function n(){var n=["ready"].concat(c.call(arguments));return t(function(){n.push(c.call(arguments)),this._q.push(n)})}var i={_q:[],_c:{},ts:(new Date).getTime(),ver:"2.0.0"},c=Array.prototype.slice;return i.init=function(t){return i._c=t,t.synchronous||i.loadtagmgr(t),this},i.loadtagmgr=function(t){var n=document.createElement("script");n.type="text/javascript",n.async=!0,n.src=t.url+"/api/tag/"+t.cid+"/lio.js";var i=document.getElementsByTagName("script")[0];i.parentNode.insertBefore(n,i)},i.ready=n(),i.send=n("send"),i.mock=n("mock"),i.identify=n("identify"),i.pageView=n("pageView"),i.bind=t(function(t){i._q.push([t,c.call(arguments,1)])}),i.block=t(function(){i._c.blockload=!0}),i.unblock=t(function(){i._c.blockload=!1}),i}(),window.jstag.init({cid:"107d418c4b7bb3debf57a3af0ce16190", url:"//c.lytics.io", min:true, loadid:false}); </script>

<!-- Facebook Pixel Code -->
<script>

	fireOrSaveJsFunctions(1,function() {

		!function (f, b, e, v, n, t, s) {
			if (f.fbq)return;
			n = f.fbq = function () {
				n.callMethod ?
					n.callMethod.apply(n, arguments) : n.queue.push(arguments)
			};
			if (!f._fbq)f._fbq = n;
			n.push = n;
			n.loaded = !0;
			n.version = '2.0';
			n.queue = [];
			t = b.createElement(e);
			t.async = !0;
			t.src = v;
			s = b.getElementsByTagName(e)[0];
			s.parentNode.insertBefore(t, s)
		}(window,
			document, 'script', 'https://connect.facebook.net/en_US/fbevents.js');

		fbq('init', '1039134266174910');
		fbq('track', "PageView");
	});
</script>

<noscript><img height="1" width="1" style="display:none"
src="https://www.facebook.com/tr?id=1039134266174910&ev=PageView&noscript=1"
/></noscript>



<!--Moat content code-->
<script>

	fireOrSaveJsFunctions(1,function(){

		(function(){function t(){for(var a=[8],e=1;2>=e;e++)a.push(8+e),a.push(8-e);a=a[Math.floor(Math.random()*a.length)];return{b:a,a:0==Math.floor(Math.random()*a)}}function k(a){var e=a=a.replace(":","");try{for(var b=0;100>b&&(a=decodeURIComponent(a),e!=a)&&!a.match(/^http(s)?\:/);b++)e=a}catch(c){}return a.replace(/(^\s+|\s+$)/g,"")}try{if(!location||!location.hostname||!location.pathname)return!1;var c=document.location.hostname.replace(/^www\./,""),u=function(){for(var a,b=document.getElementsByTagName("meta"),c,d=0,f=b.length;d<f;d++)if(c=b[d],"og:title"===c.getAttribute("property")){a=c.getAttribute("content");break}a||(a=document.title||"Untitled");return a}(),b={},b=function(a,b,c){a.l1=b;a.l2=c;a.l3="__page__";a.l4="-";return a}(b,c,u),l=(new Date).getTime(),m=Math.floor(Math.random()*Math.pow(10,12)),d,f;f=t();f.a?d=f.b:d=0;b.zmoatab_cm=d;b.t=l;b.de=m;b.zMoatAB_SNPT=!0;var g;d?g=d:g=1;var n;n=f?f.a?!0:!1:!0;var c=[],p=[k(b.l1),k(b.l2),k(b.l3),k(b.l4)].join(":"),v="https://wve3oiypgri4-a.akamaihd.net/z.gif?e=17&d="+
			encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&mp=1&ac=1&pl=1&bq=10&vc=2&cs=0",w="https://px.moatads.com/pixel.gif?e=17&d="+encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&mp=0&ac=1&pl=1&bq=10&ad_type=img&vc=2&cs=0",x="https://px.moatads.com/pixel.gif?e=17&d="+encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&ku=1&ac=1&pl=1&bq=10&ad_type=img&vc=2&cs=0";n&&((new Image).src=v,(new Image).src=w);for(var q in b)c.push(q+"="+encodeURIComponent(b[q]));
			var c=c.join("&"),c=c+"&vc=2",h=document.createElement("script");h.type="text/javascript";h.async=!0;n&&(h.onerror=function(){(new Image).src=x});var r=document.getElementsByTagName("script")[0];r.parentNode.insertBefore(h,r);h.src="https://z.moatads.com/healthlinecontent451781663455/moatcontent.js#"+c}catch(a){try{var y="//pixel.moatads.com/pixel.gif?e=24&d=data%3Adata%3Adata%3Adata&i=MOATCONTENTABSNIPPET1&vc=2&ac=1&k="+encodeURIComponent(a)+"&j="+encodeURIComponent(document.referrer)+"&cs="+(new Date).getTime();
			(new Image).src=y}catch(e){}}})();


	});

</script>
</head>
<body id="drugs" class="article v2 tabbed lang_en">
<div itemscope="" itemtype="http://schema.org/NewsArticle">








<noscript>
<div class="header_message enable_js error">
<p>For full functionality, it is necessary to enable JavaScript. Here are <a href="http://www.enable-javascript.com" rel="noopener noreferrer" target="_blank">instructions how to enable JavaScript</a> in your web browser.</p>
</div>


<div class="fullscreen_outer">
	<div class="fullscreen_inner">
		<h5>Welcome to Medical News Today</h5>
		<p>
			Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a <a href="https://www.medicalnewstoday.com/privacy-policy#vendors" target="_blank">current list</a>) using cookies and similar automatic collection tools in order to a) personalize content and/or offers on our site or other sites, b) communicate with you upon request, and/or c) for additional reasons upon notice and, when applicable, with your consent.</p>
		<p>
			Healthline Media, Inc. is based in and operates this site from the United States. Any data you provide will be primarily stored and processed in the United States, pursuant to the laws of the United States, which may provide lesser privacy protections than European Economic Area countries.
		</p>
		<p>
			By clicking “accept” below, you acknowledge and grant your consent for these activities unless and until you withdraw your consent using our <a href="https://www.healthline.com/rights-request" rel="noopener noreferrer" target="_blank">rights request form</a>. Learn more in our <a href="https://www.medicalnewstoday.com/privacy-policy" target="_blank">Privacy Policy</a>.
		</p>
	</div>
</div>


</noscript>
<div id="header_message" class="new_menu">
<input type="hidden" id="is_usermobile" name="is_usermobile" value="0">





 
</div>

<div id="navigation" class="container default_menu new_menu">

	<div class="row">

		<nav role="navigation" class="main_nav">
		
			<ul class="main_nav left"> 	
				<li class="menu_topics">
					<a href="#"></a>
		
					
<div class="menu_panel fullscreen_outer topics">
  <div class="menu_panel fullscreen_inner">
    <div class="row">
					
					
					<div class="topics">
												
							<div class="menu_topic_container">
							
								<ul class="topic_headings">
									<li class="topic_headings_top"><span>Top categories</span>
										<ul class="topic_popular_list">
											<li><a href="/categories/blood">Blood / Hematology</a></li>
<li><a href="/categories/bones">Bones / Orthopedics</a></li>
<li><a href="/categories/breast_cancer">Breast Cancer</a></li>
<li><a href="/categories/colorectal_cancer">Colorectal Cancer</a></li>
<li><a href="/categories/depression">Depression</a></li>
<li><a href="/categories/gastrointestinal">GastroIntestinal</a></li>
<li><a href="/categories/hypertension">Hypertension</a></li>
<li><a href="/categories/lymphoma">Lymphoma</a></li>
<li><a href="/categories/mens_health">Men's Health</a></li>
<li><a href="/categories/neurology">Neurology / Neuroscience</a></li>
<li><a href="/categories/nutrition-diet">Nutrition / Diet</a></li>
<li><a href="/categories/pain">Pain / Anesthetics</a></li>
<li><a href="/categories/prostate">Prostate / Prostate Cancer</a></li>
<li><a href="/categories/psoriasis">Psoriasis</a></li>
<li><a href="/categories/respiratory">Respiratory</a></li>
<li><a href="/categories/sexual_health">Sexual Health / STDs</a></li>
<li><a href="/categories/stroke">Stroke</a></li>
<li><a href="/categories/tuberculosis">Tuberculosis</a></li>
<li><a href="/categories/urology-nephrology">Urology / Nephrology</a></li>
<li><a href="/categories/womens_health">Women's Health</a></li>
										</ul> 	
									</li>
																											
									<li class="topic_headings_all"><span>All categories</span>
										<ul class="topic_all_list">
											<li><a href="/categories#a">A - B</a></li>
											<li><a href="/categories#c">C - D</a></li>
											<li><a href="/categories#e">E - G</a></li>
											<li><a href="/categories#h">H - L</a></li>
											<li><a href="/categories#m">M - O</a></li>
											<li><a href="/categories#p">P - R</a></li>
											<li><a href="/categories#s">S - Z</a></li>
											<li><a href="/categories">All Topics</a></li>
										</ul>	
									</li>


								</ul> 									
							</div> 	
						
							<div class="menu_cta_container">
							
									<span>More</span>	
																		
									<ul class="topic_more_list">
										<li class="menu_newsletter_cta"><a href="#" class="new_reg_signup menu_item_link" data-signup-source="menu_item_link"><span class="icon_container"></span>Sign up for our newsletter</a></li>
										<li class="menu_discover_cta"><a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-menu-cta-2017.png" height="15" width ="34"/>Discover in-depth, condition specific articles written by our in-house team.</a></li>

									</ul> 	
	
							</div> 	
			
			
											
					</div> 	
					</div> 	
					</div> 	
											
											
											
					</div> 	
			  
				</li> 	

					<li class="menu_newsletter">

						<a href="#" data-signup-source="menu_newsletter_link" class="menu-newsletter-link  new_reg_signup"><div>Newsletter</div></a>

					</li> 	

			</ul>
				
			<div class="logo">
				<a href="/" accesskey="h" title="Medical News Today : Home">
					<img src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-2017-640-60.png" alt="MNT home">
					<p>MNT - Hourly Medical News Since 2003</p>
				</a>
			</div> 	
				
			<ul class="main_nav right"> 	

			<div id="search_area">


<div id="searchwrapper" class="">



<div class="search_trigger">

<form id="searchFormHeader" action="/search" >
<input type="text" id="header_search" placeholder="" class="searchbox" name="q" maxlength="150" autocomplete="off"/>
<button class="screen_only black float_right" id="header_search_button" type="submit" id="" title="Search MNT" value="">Search</button>
<button class="mobile_only blue float_right" id="header_search_button" type="submit" title="Search MNT" value="">Go</button>
<input type="hidden" name="p" value="1" />
</form>



</div>
	

</div>
</div>	
			


					<li class="menu_login">
						<a href="#" id="menu_login_link">
							<div>

							</div>
						</a>
					</li>
			</ul>
		</nav>	

	</div> 	

</div> 
<div id="navigation_scroll" class="container light  ">

<div class="row">

<nav id="subnavigation">

			<ul class="main_nav left"> 	
				<li class="menu_topics">
					<a href="#"></a>
		
					
<div class="menu_panel fullscreen_outer topics">
  <div class="menu_panel fullscreen_inner">
    <div class="row">
					
					
					<div class="topics">
												
							<div class="menu_topic_container">
							
								<ul class="topic_headings">
									<li class="topic_headings_top"><span>Top categories</span>
										<ul class="topic_popular_list">
											<li><a href="/categories/blood">Blood / Hematology</a></li>
<li><a href="/categories/bones">Bones / Orthopedics</a></li>
<li><a href="/categories/breast_cancer">Breast Cancer</a></li>
<li><a href="/categories/colorectal_cancer">Colorectal Cancer</a></li>
<li><a href="/categories/depression">Depression</a></li>
<li><a href="/categories/gastrointestinal">GastroIntestinal</a></li>
<li><a href="/categories/hypertension">Hypertension</a></li>
<li><a href="/categories/lymphoma">Lymphoma</a></li>
<li><a href="/categories/mens_health">Men's Health</a></li>
<li><a href="/categories/neurology">Neurology / Neuroscience</a></li>
<li><a href="/categories/nutrition-diet">Nutrition / Diet</a></li>
<li><a href="/categories/pain">Pain / Anesthetics</a></li>
<li><a href="/categories/prostate">Prostate / Prostate Cancer</a></li>
<li><a href="/categories/psoriasis">Psoriasis</a></li>
<li><a href="/categories/respiratory">Respiratory</a></li>
<li><a href="/categories/sexual_health">Sexual Health / STDs</a></li>
<li><a href="/categories/stroke">Stroke</a></li>
<li><a href="/categories/tuberculosis">Tuberculosis</a></li>
<li><a href="/categories/urology-nephrology">Urology / Nephrology</a></li>
<li><a href="/categories/womens_health">Women's Health</a></li>
										</ul> 	
									</li>
																											
									<li class="topic_headings_all"><span>All categories</span>
										<ul class="topic_all_list">
											<li><a href="/categories#a">A - B</a></li>
											<li><a href="/categories#c">C - D</a></li>
											<li><a href="/categories#e">E - G</a></li>
											<li><a href="/categories#h">H - L</a></li>
											<li><a href="/categories#m">M - O</a></li>
											<li><a href="/categories#p">P - R</a></li>
											<li><a href="/categories#s">S - Z</a></li>
											<li><a href="/categories">All Topics</a></li>
										</ul>	
									</li>

								</ul> 									
							</div> 	
						
							<div class="menu_cta_container">
							
									<span>More</span>	
																		
									<ul class="topic_more_list">

										<li class="menu_newsletter_cta"><a href="#" class="new_reg_signup menu_item_link" data-signup-source="menu_item_link"><span class="icon_container"></span>Sign up for our newsletter</a></li>
										<li class="menu_discover_cta"><a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-menu-cta-2017.png" height="15" width ="34"/>Discover in-depth, condition specific articles written by our in-house team.</a></li>

									</ul> 	
	
							</div> 	
			
			
											
					</div> 	
					</div> 	
					</div> 	
											
											
											
					</div> 	
			  
				</li> 

					<li class="menu_newsletter">

						<a href="#" data-signup-source="menu_newsletter_link" class="menu-newsletter-link  new_reg_signup"><div>Newsletter</div></a>

					</li> 
				
			</ul>
				
			<div class="logo">
				<a href="/" accesskey="h" title="Medical News Today : Home">
					<img src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-2017-640-60.png" alt="MNT home">
					<p>MNT - Hourly Medical News Since 2003</p>
				</a>
			</div> 	
				
			<ul class="main_nav right"> 	
				
					

			<div id="search_area">


<div id="searchwrapper" class="">



<div class="search_trigger">

<form id="searchFormHeader" action="/search" >
<input type="text" id="header_search" placeholder="" class="searchbox" name="q" maxlength="150" autocomplete="off"/>
<button class="screen_only black float_right" id="header_search_button" type="submit" id="" title="Search MNT" value="">Search</button>
<button class="mobile_only blue float_right" id="header_search_button" type="submit" title="Search MNT" value="">Go</button>
<input type="hidden" name="p" value="1" />
</form>



</div>
	

</div>
</div>	
			


					<li class="menu_login">
						<a href="#" id="menu_login_link">
							<div>

							</div>
						</a>

					</li>
			</ul>
		
		</nav>	

	</div> 	

</div> <div class="modal fade" id="picModal" tabindex="-1" role="dialog" style="z-index: 1040; padding-left:0;">
	<div class="modal-dialog" role="document">
		<div class="modal-content" style="">
			<div class="modal-header">
				<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>

			</div>
			<div class="modal-body" style="text-align: center;">

				<div id="picModal-loading-animation">

					<i class="fa fa-circle-o-notch fa-spin fa-3x fa-fw"></i>
					<span class="sr-only">Loading...</span>

				</div>


				<span class="helper" style="display: inline-block;height: 100%;vertical-align: middle;"></span> <img id="origin-img" src="">

			</div>

		</div>
	</div>
</div>


<div class="modal fade site_modal modal_gdpr" tabindex="-1" role="dialog" aria-hidden="true" id="gdprModal" data-backdrop="static" data-keyboard="false">
	<div class="modal-dialog" role="document">

		<div class="modal-content">

			<div class="modal-header">
			</div>

			<div class="modal-body container" onscroll="modalScroll()">
				<div class="fullscreen_outer article_header">
					<div class="fullscreen_inner">
						<h5>Please accept our privacy terms</h5>
						<p>
							We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our <a href="https://www.medicalnewstoday.com/advertising" target="_blank">Advertising Policy</a> and <a href="https://www.medicalnewstoday.com/privacy-policy" target="_blank">Privacy Policy</a>. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.
						</p>
					</div>
				</div>
			</div>
			<div class="modal-footer container gradient">
				<div class="article_header">
					<button class="primary" onclick="GDPRAccept()">ACCEPT AND CONTINUE TO SITE</button>
					<button class="secondary" onclick="confirmDeny()">Deny permission</button>
				</div>
			</div>

		</div>
		<div class="scroll_more hidden">
			<button class="primary" onclick="scrollAccept()">Scroll to Accept</button>
		</div>

	</div>
</div>



	<!--for new newsletter sign up proc-->
	<div class="modal fade registration_modal_form" tabindex="-1" role="dialog" aria-hidden="true" id="registrationModal">
		<div class="modal-dialog" role="document">
			<div class="modal-content modal_reg" id="registration_modal_form">
									<div class="modal-header screen_only">
						<h4 class="modal-title">Get the MNT newsletter</h4>
						<button type="button" class="close" data-dismiss="modal"></button>
					</div>
				


				<div class="modal-body" id="registration_start">

					<div class="iframe_scroll_container">

						<!--form migration start-->

						<form id="new-reg-form">
							<div class="form container_reg">
								<div class="form header_reg">

									<div class="form-group">
										<input type="email" name="formEmail" style="margin-bottom: 20px;" class="form-control newsletterFormEmail" id="inputEmail" placeholder="Enter email address" value="">
									</div>

									<!--error meesage place holder-->
									<div id="signFinishErrorHolder" class="errorHolder"></div>


									<div id="registration_modal_message" class="form-group">


										<!--while user finish the register process, something info need to tell user, but not error message-->
										<div id="newsletterRegisterInfo" class="message start">

										</div>


										<!--User will see the message everytime open the register modal-->
										<div id="newsletterTypeMessage" class="message start">

											<p>
												Enter your email address to subscribe to <span id="selectedCategoryText">our most top categories</span>
											</p>

											

<p>Your <a href="/privacy-policy" title="Privacy policy">privacy</a> is important to us.</p>

										</div>

									</div>

								</div>
							</div>

							<!--set by js-->
							<input type="hidden" id="newsletterCategories" name="newsletterCategories" value="">
							<input type="hidden" id="newsletterTypeMessageHTMLBackup" name="newsletterTypeMessageHTMLBackup" value="">

						</form>

						<!--form migration end-->

					</div>
				</div>


				<div class="modal-footer">
					<button type="button" id="email-start-signup-btn" class="btn btn-success btn-block">CONTINUE</button>

<!--					<button type="button" id="email-finish-signup-btn" class="btn btn-danger btn-block" data-dismiss="modal">OK</button>-->
				</div>				

			</div>



		</div><!-- /.modal-dialog -->
	</div><!-- /.modal -->



<div class="modal fade email-an-article-modal" tabindex="-1" role="dialog" aria-hidden="true" id="email-an-article-modal">
	<div class="modal-dialog" role="document">
		<div class="modal-content">
			<div class="modal-header">
				<h3 class="">Email an article</h3>
				<button type="button" class="close" data-dismiss="modal"></button>
			</div>
			<div class="modal-body">
				<p>You have chosen to share the following article:</p>
				<p><b id="email-an-article-title">How elderberries can help you fight the flu</b></p>
				<p>To proceed, simply complete the form below, and a link to the article will be sent by email on your behalf.<br>
					<b>Note:</b> Please don't include any URLs in your comments, as they will be removed upon submission.</p>
				<p>We do not store details you enter into this form. Please see our <a href="/privacy-policy" title="Read our Privacy Policy" target="_blank">privacy policy</a> for more information.</p>

				<form id="email-an-article-form">
					<fieldset class="form-container">
						<div>
							<label><em>*</em>Your Name (max. 30 chars)</label>
							<input id="fromName" type="text" name="fromName" maxlength="30" value="" required>
							<label for="fromName" generated="true" class="formError" style="display: none">The field 'Your Name' is required.</label>
						</div>
						<div>
							<label><em>*</em>Email Address</label>
							<input id="fromEmailAddress" class="formEmail" type="email" name="fromEmailAddress" maxlength="100" value="" required>
							<label for="fromEmailAddress" generated="true" class="formError" style="display: none">This is not a valid email address.</label>
						</div>
						<div>
							<label><em>*</em>Friend's Name (max. 30 chars)</label>
							<input id="toName" type="text" name="toName" maxlength="30" value="" required>
							<label for="toName" generated="true" class="formError" style="display: none">The field 'Friend's Name' is required.</label>
						</div>
						<div>
							<label><em>*</em>Friend's Email Address</label>
							<input id="toEmailAddress" type="email" name="toEmailAddress" maxlength="100" value="" required>
							<label for="toEmailAddress" generated="true" class="formError" style="display: none">The field 'Friend's Email Address' is required.</label>
						</div>

					</fieldset>


					<div id="email-an-article-reCAPTCHA" class="g-recaptcha" data-sitekey="6Le68KEUAAAAAOKVyWLvP5U0Dl2HT9dqR0J1hx7z"></div>




					<div class="buttonrow">
						<button type="submit" id="email_submit" class="btn-form form-submit secure">Send securely</button>
						<span class="form_secure_icon"></span>
					</div>

				</form>

				<div class="robots-nocontent">
					<div id="email-an-article-success" class="information"  style="display: none">
						<h2 class="message_box">Message sent successfully</h2>
						<p><b>The details of this article have been emailed on your behalf.</b></p>
						<p><a href="/" title="Click here to return to the MNT homepage">Click here</a> to return to the Medical News Today home page.</p>
					</div>
				</div>
			</div>
		</div>
	</div><!-- /.modal-dialog -->
</div>










<hr class="css_h1ksn" >






<div class="container"> 

<div class="row site_header"> 

<article  >

			<div class="col-xs-12 col-sm-12 col-md-12 col-lg-12 article_header"> 		<!-- Leaderboard BANNER advert -->

<div id="dlb1_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb1_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB1',
			"slotContainer":'dlb1_container'		});
	</script>
	</div>
	<span class='bt-uid-tg' data-uid='5b84646203-160' style='display: none !important' data-style='width: 728px;height: 90px;background: rgba(255, 255, 255, 0.5);border: 2px solid #888;box-sizing: border-box;margin: 0 auto 0;'></span>

</div>






<!-- /header_ad code -->
<h1 itemprop="headline">Tecfidera (dimethyl fumarate)</h1>

</div> 	<div class="col-xs-12 col-sm-12 col-md-8 col-lg-8 main_content"> 	<div id="article_date">
			<span class="date_reviewed screen_only">Last reviewed		<time itemprop="lastReviewed" datetime="2018-09-27">
		Thu 27 September 2018		</time></span>
		
		<span class="date_reviewed mobile_only">Last reviewed		Thu 27 Sep 2018</span>
		
			</div>
		<div class="author_top">
	<span class='author_byline'>By MNT’s Medical Network</span>	</div>
				<div class="reviewer_top">
			<span class='reviewer_byline'>Reviewed by <a href='/reviewers' class='article_author' rel='author' title='MNT medical review team' >Lindsay Slowiczek, PharmD</a></span>			</div>
			<span class="clearfix"></span>

<div class="article_body">
	<div itemprop="articleBody">
	<div class="article_toc collapsed article_collapsed">
<a class="collapsed__click" href="#"><i class="collapsed__icon"></i>Table of contents</a><ol class="collapsed__tabs hide">
<li><a href="#generic-name">Generic name</a></li>









<li><a href="#side-effects">Side effects</a></li>









<li><a href="#uses">Uses</a></li>









<li><a href="#alternatives">Alternatives</a></li>









<li><a href="#tecfidera-vs-other-drugs">Tecfidera vs. other drugs</a></li>









<li><a href="#dosage">Dosage</a></li>









<li><a href="#how-to-take">How to take</a></li>









<li><a href="#pregnancy">Pregnancy</a></li>









<li><a href="#breastfeeding">Breastfeeding</a></li>









<li><a href="#how-it-works">How it works</a></li>









<li><a href="#tecfidera-and-alcohol">Tecfidera and alcohol</a></li>









<li><a href="#interactions">Interactions</a></li>









<li><a href="#common-questions">Common questions</a></li>









<li><a href="#overdose">Overdose</a></li>









<li><a href="#warnings">Warnings</a></li>









<li><a href="#expiration">Expiration</a></li>









<li><a href="#professional-information">Professional information</a></li>









</ol>
</div>









<h2>What is Tecfidera?</h2>









<p>Tecfidera (dimethyl fumarate) is a brand-name prescription medication. It's used to treat relapsing forms of <a href="/articles/37556.php" title="Multiple sclerosis: What you need to know" class="keywords">multiple sclerosis</a> (MS).</p>









<p>Tecfidera is classified as a disease-modifying therapy for MS. It reduces the risk of MS relapse by up to <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">49 percent</a> over two years. It also reduces the risk of having worsening physical disability by about <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">38 percent</a>.</p>









<p>Tecfidera comes as a delayed-released oral capsule. It's available in two strengths: 120-mg capsules and 240-mg capsules.</p>









 <span class="anchor" id="generic-name"></span>
<h2>Tecfidera generic name</h2>









<p>Tecfidera is a brand-name drug. It's not currently available as a generic drug.</p>









<p>Tecfidera contains the drug dimethyl fumarate.</p>









 <span class="anchor" id="side-effects"></span>
<!--[MMR]--><!--[END MMR]--><h2>Tecfidera side effects</h2>









<p>Tecfidera can cause mild or serious side effects. The following list contains some of the key side effects that may occur while taking Tecfidera. This list doesn't include all possible side effects.</p>









<p>For more information on the possible side effects of Tecfidera, or tips on how to deal with a troubling side effect, talk with your doctor or pharmacist.</p>









<h3>More common side effects</h3>









<p>The more common side effects of Tecfidera include:</p>









<ul>
<li>flushing (reddening of the face and neck)</li>









<li><a href="/articles/163484.php" title="What to know about indigestion or dyspepsia" class="keywords">stomach upset</a></li>









<li>stomach pain</li>









<li><a href="/articles/158634.php" title="What you should know about diarrhea" class="keywords">diarrhea</a></li>









<li>nausea</li>









<li>vomiting</li>









<li>itchy skin</li>









<li>rash</li>









</ul>
<p>These side effects may decrease or go away within a few weeks. If they're more severe or don't go away, talk to your doctor or pharmacist.</p>









<h3>Serious side effects</h3>









<p>Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you're having a medical emergency. Serious side effects can include the following:</p>









<ul>
<li>severe flushing</li>









<li>progressive multifocal leukoencephalopathy (PML)</li>









<li>decreased white blood cell levels (lymphopenia)</li>









<li>liver damage</li>









<li>severe allergic reaction</li>









</ul>
<p>See below for information about each serious side effect.</p>









<h3>PML</h3>









<p>Progressive multifocal leukoencephalopathy (PML) is a life-threatening infection of the brain caused by the JC virus. It usually only happens in people whose immune system isn't fully working. Very rarely, PML has occurred in people with MS who were taking Tecfidera. In these cases, the people who developed PML also had decreased white blood cell levels.</p>









<p>To help prevent PML, your doctor will do blood tests regularly during your treatment to check your white blood cell levels. If your levels get too low, your doctor may recommend that you stop taking Tecfidera.</p>









<p>Your doctor will also monitor you for symptoms of PML while you take the drug. Symptoms may include:</p>









<ul>
<li>weakness on one side of your body</li>









<li>vision problems</li>









<li>clumsiness</li>









<li>memory problems</li>









<li>confusion</li>









</ul>
<p>If you have these symptoms while taking Tecfidera, call your doctor right away. Your doctor will likely do tests to check whether you have PML, and they may stop your treatment with Tecfidera.</p>









<h3>Flushing</h3>









<p>Flushing (reddening of your face or neck) is a common side effect of Tecfidera. It happens in up to <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">40 percent</a> of people who take the drug. Flushing effects typically occur soon after you start taking Tecfidera, and then improve or go away entirely over a period of several weeks.</p>









<p>In most cases, flushing is mild to moderate in severity and symptoms include:</p>









<ul>
<li>feelings of warmth in the skin</li>









<li>skin redness</li>









<li>itching</li>









<li>feeling of burning</li>









</ul>
<p>For some, symptoms of flushing can become severe and intolerable. About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">3 percent</a> of people who take Tecfidera end up stopping the drug due to severe flushing.</p>









<p>Taking Tecfidera with food can help reduce flushing. Taking an <a href="/articles/161255.php" title="Uses, benefits, and risks of aspirin" class="keywords">aspirin</a> 30 minutes before taking Tecfidera can also help.</p>









<h3>Lymphopenia</h3>









<p>Tecfidera can cause lymphopenia, a decreased level of white blood cells called lymphocytes. Lymphopenia can increase your risk of infections. Symptoms of lymphopenia can include:</p>









<ul>
<li><a href="/articles/168266.php" title="Fever: What you need to know" class="keywords">fever</a></li>









<li>enlarged lymph nodes</li>









<li>painful joints</li>









</ul>
<p>Your doctor will do blood tests before and during your treatment with Tecfidera. If your lymphocyte levels become too low, your doctor may suggest that you stop taking Tecfidera for a set amount of time, or permanently.</p>









<h3>Liver effects</h3>









<p>Tecfidera can cause liver side effects. It may increase levels of certain liver enzymes that are measured by blood tests. This increase usually happens during the first six months of treatment.</p>









<p>For most people, these increases don't cause problems. But for a small number of people, they may become severe and indicate liver damage. Symptoms of liver damage can include:</p>









<ul>
<li><a href="/articles/248002.php" title="Fatigue: Why am I so tired and what can I do about it?" class="keywords">fatigue</a></li>









<li>loss of appetite</li>









<li>yellowing of your skin or the whites of your eyes</li>









</ul>
<p>Before and throughout your treatment with Tecfidera, your doctor will do blood tests to check your liver function. If your liver enzymes increase too much, your doctor may have you stop taking this drug.</p>









<h3>Severe allergic reaction</h3>









<p>Serious allergic reactions, including <a href="/articles/216062.php" title="Anaphylaxis: Signs, causes, and treatment" class="keywords">anaphylaxis</a>, can occur in some people who take Tecfidera. This can occur at any time during treatment. Symptoms of an allergic reaction can include:</p>









<ul>
<li>trouble breathing</li>









<li>skin rash or <a href="/articles/157260.php" title="What are hives (urticaria)?" class="keywords">hives</a>
</li>









<li>swelling of your lips, tongue, throat</li>









</ul>
<p>If you have an allergic reaction, call your doctor or local poison control center right away. If your symptoms are severe, call 911 or go to the nearest emergency room.</p>









<p>If you've had a serious allergic reaction to this drug in the past, you may not be able to take it again. Using the drug again could be fatal. If you've had a reaction to this medication before, talk to your doctor before taking it again.</p>









<h3>Rash</h3>









<p>About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">8 percent</a> of people who take Tecfidera get a mild skin rash after taking Tecfidera for a few days. The rash may go away with continued use. If it doesn't go away or it becomes bothersome, talk to your doctor.</p>









<p>If a rash appears suddenly after you take the drug, it could be an allergic reaction. If you also have trouble breathing or swelling of your lips or tongue, this could be a severe anaphylactic reaction. <strong>If you think you're having a severe allergic reaction to this drug, call 911.</strong></p>









<h3>Hair loss</h3>









<p><a href="/articles/70956.php" title="What's to know about alopecia areata?" class="keywords">Hair loss</a> isn't a side effect that has occurred in studies of Tecfidera. However, some people who take Tecfidera have had hair loss.</p>









<p>In one <a href="https://www.msard-journal.com/article/S2211-0348(16)30025-6/fulltext" target="_blank" rel="noopener">report</a>, a woman who started taking Tecfidera began to lose hair after taking the drug for two to three months. Her hair loss slowed after she continued taking the drug for two more months, and her hair began to grow back.</p>









<h3>Weight gain/Weight loss</h3>









<p>Weight gain or weight loss isn't a side effect that has occurred in studies of Tecfidera. However, some people who take the drug have had weight gain. Some others have had weight loss while taking Tecfidera. It's not clear if Tecfidera is the cause of weight gain or loss.</p>









<h3>Fatigue</h3>









<p>People who take Tecfidera can experience fatigue. In one study, fatigue happened in <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">17 percent</a> of people who took it. This side effect may decrease or go away with continued use of the drug.</p>









<h3>Stomach pain</h3>









<p>About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">18 percent</a> of people who take Tecfidera have stomach pain. This side effect is most common during the first month of treatment and usually decreases or goes away with continued use of the drug.</p>









<h3>Diarrhea</h3>









<p>About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">14 percent</a> of people who take Tecfidera have diarrhea. This side effect is most common during the first month of treatment and usually decreases or goes away with continued use.</p>









<h3>Effect on sperm or male fertility</h3>









<p>Human studies haven't evaluated the effect of Tecfidera on sperm or male fertility. In animal studies, Tecfidera didn't affect fertility, but studies in animals don't always predict what will happen in humans.</p>









<h3>Headache</h3>









<p>Some people who take Tecfidera have <a href="/articles/73936.php" title="What is causing this headache?" class="keywords">headaches</a>. However, it's unclear if Tecfidera is the cause. In one study, <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">16 percent</a> of people who took Tecfidera had headaches, but headaches happened more often in people who took a <a href="/articles/306437.php" title="Placebos: The power of the placebo effect" class="keywords">placebo</a> pill.</p>









<h3>Itching</h3>









<p>About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">8 percent</a> of people who take Tecfidera have itchy skin. This effect may go away with continued use of the drug. If it doesn't go away or if it becomes bothersome, talk to your doctor.</p>









<h3>Depression</h3>









<p>Some people who take Tecfidera have a depressed mood. However, it's unclear if Tecfidera is the cause. In one study, <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">8 percent</a> of people who took Tecfidera had feelings of <a href="/kc/depression-causes-symptoms-treatments-8933" title="What is depression and what can I do about it?" class="keywords">depression</a>, but this happened more often in people who took a placebo pill.</p>









<p>If you have symptoms of depression that become bothersome, talk with your doctor about ways to improve your mood.</p>









<h3>Shingles</h3>









<p>In clinical studies, Tecfidera didn't increase the risk of <a href="/articles/154912.php" title="What is shingles?" class="keywords">shingles</a>. However, there's a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794808/" target="_blank" rel="noopener">report</a> of shingles in a woman with multiple sclerosis who took Tecfidera.</p>









<h3>Cancer</h3>









<p>In clinical studies, Tecfidera didn't increase the risk of <a href="/info/cancer-oncology/" title="What is Cancer?" class="keywords">cancer</a>. In fact, some researchers are <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956641/" target="_blank" rel="noopener">investigating</a> whether Tecfidera might help prevent or treat some cancers.</p>









<h3>Nausea</h3>









<p>About <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">12 percent</a> of people who take Tecfidera have nausea. This effect may go away with continued use of the drug. If it doesn't go away or if it becomes bothersome, talk to your doctor.</p>









<h3>Constipation</h3>









<p><a href="/articles/150322.php" title="What to know about constipation" class="keywords">Constipation</a> hasn't been reported in clinical studies of Tecfidera. However, people who take Tecfidera sometimes have constipation. It's not clear if this is a side effect of Tecfidera.</p>









<h3>Bloating</h3>









<p>Bloating hasn't been reported in clinical studies of Tecfidera. However, people who take Tecfidera sometimes have bloating. It's not clear if this is a side effect of Tecfidera.</p>









<h3>Insomnia</h3>









<p><a href="/articles/9155.php" title="Insomnia: Everything you need to know" class="keywords">Insomnia</a> (trouble falling asleep or staying asleep) hasn't been reported in clinical studies of Tecfidera. However, people who take Tecfidera sometimes have insomnia. It's not clear if this is a side effect of the drug.</p>









<div id="onequarter-of-article"></div>
<h3>Bruising</h3>









<p>In clinical studies, Tecfidera didn't increase the risk of bruising. However, many people who have MS say that they often having bruising. The reason for this isn't clear. A few theories are listed below.</p>









<ul>
<li>As MS progresses, maintaining balance and coordination can become more difficult. This could result in bumping into things or falling, both of which could cause bruising.</li>









<li>A person with MS who takes Tecfidera might also take aspirin to help prevent flushing. Aspirin can increase bruising.</li>









<li>People who have taken steroids may have thinner skin, which can make them bruise more easily. So people with MS who have a history of steroid use could experience more bruising.</li>









</ul>
<p>If you're concerned about bruising while taking Tecfidera, talk with your doctor. Your doctor may do blood tests to check for other causes.</p>









<h3>Joint pain</h3>









<p>Joint pain can occur in people who take Tecfidera. In one study, <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">12 percent</a> of people who took Tecfidera had joint pain. Another <a href="https://www.jns-journal.com/article/S0022-510X(16)30439-7/fulltext" target="_blank" rel="noopener">report</a> described three people who had moderate to severe joint or muscle pain after starting Tecfidera.</p>









<p>This side effect may decrease or go away with continued use of the drug. Joint pain can also improve when Tecfidera is stopped.</p>









<h3>Dry mouth</h3>









<p><a href="/articles/187640.php" title="Everything you need to know about dry mouth" class="keywords">Dry mouth</a> hasn't been reported in clinical studies of Tecfidera. However, people who take Tecfidera sometimes have dry mouth. It's not clear if this is a side effect of Tecfidera.</p>









<h3>Effects on eyes</h3>









<p>Eye-related side effects haven't been reported in clinical studies of Tecfidera. However, some people who take the drug have said that they've had symptoms such as:</p>









<ul>
<li><a href="/articles/170743.php" title="What is dry eye and how can I get rid of it?" class="keywords">dry eyes</a></li>









<li>eye twitching</li>









<li>blurry vision</li>









</ul>
<p>It's not clear if these eye effects are caused by the drug or by something else. If you have these effects and they don't go away or they become bothersome, talk with your doctor.</p>









<h3>Flu-like symptoms</h3>









<p>The <a href="/articles/15107.php" title="All you need to know about flu" class="keywords">flu</a> or flu-like symptoms have occurred in studies of people taking Tecfidera. In one such study, <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">6 percent</a> of people who took the drug had these effects, but the effects happened more often in people who took a placebo pill.</p>









<h3>Long-term side effects</h3>









<p>Studies evaluating the effects of Tecfidera have lasted from two to six years. In <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919132/" target="_blank" rel="noopener">one study</a> lasting six years, the most common side effects were:</p>









<ul>
<li>MS relapse</li>









<li>
<a href="/articles/155412.php" title="Strep throat: Causes, diagnosis, and treatments" class="keywords">sore throat</a> or runny nose</li>









<li>flushing</li>









<li>respiratory infection</li>









<li><a href="/articles/189953.php" title="What to know about urinary tract infections" class="keywords">urinary tract infection</a></li>









<li>headache</li>









<li>diarrhea</li>









<li>fatigue</li>









<li>stomach pain</li>









<li>pain in the back, arms, or legs</li>









</ul>
<p>If you're taking Tecfidera and have side effects that don't go away or become severe or bothersome, talk with your doctor. They may suggest ways to lessen or eliminate the side effects, or they may suggest that you stop taking the drug.</p>









 <span class="anchor" id="uses"></span>
<h2>Tecfidera uses</h2>









<p>Tecfidera is approved by the Food and Drug Administration (FDA) for treating multiple sclerosis (MS).</p>









<h3>Tecfidera for MS</h3>









<p>Tecfidera is approved for treating relapsing forms of MS, the most common forms of MS. In these forms, attacks of worsening or new symptoms occur (relapse), followed by periods of partial or complete recovery (remission).</p>









<p>Tecfidera reduces the risk of MS relapse by up to <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">49 percent</a> over two years. It also reduces the risk of having worsening physical disability by about <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">38 percent</a>.</p>









<h3>Tecfidera for psoriasis</h3>









<p>Tecfidera is used off-label to treat plaque <a href="/info/psoriasis/" title="What is Psoriasis?" class="keywords">psoriasis</a>. Off-label use is when a drug is approved to treat one condition but is used to treat a different condition.</p>









<p>In a clinical <a href="https://www.ncbi.nlm.nih.gov/pubmed/27515097" target="_blank" rel="noopener">study</a>, about 33 percent of people taking Tecfidera had their plaques clear or almost completely clear after 16 weeks of treatment. About 38 percent of people taking the drug had a 75 percent improvement in an index of plaque severity and area affected.</p>









 <span class="anchor" id="alternatives"></span>
<!--[DLB]--><!-- Leaderboard BANNER advert -->

<div id="dlb2_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb2_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB2',
			"slotContainer":'dlb2_container'		});
	</script>
	</div>
	<span class='bt-uid-tg' data-uid='5b846471dd-160' style='display: none !important' ></span>

</div>






<!-- /header_ad code --><!--[END DLB]--><h2>Alternatives to Tecfidera</h2>









<p>Several medications are available to treat relapsing forms of multiple sclerosis (MS). Examples of these medications include:</p>









<ul>
<li>interferon beta-1a (Avonex, Rebif)</li>









<li>interferon beta-1b (Betaseron)</li>









<li>glatiramer acetate (Copaxone, Glatopa)</li>









<li>IV immunoglobulin (Bivigam, Gammagard, others)</li>









<li>monoclonal antibodies such as:</li>









<ul>
<li>alemtuzumab (Lemtrada)</li>









<li>natalizumab (Tysabri)</li>









<li>rituximab (Rituxan)</li>









<li>ocrelizumab (Ocrevus)</li>









</ul>
<li>fingolimod (Gilenya)</li>









<li>teriflunomide (Aubagio)</li>









</ul>
<p>Note: Some of the drugs listed here are used off-label to treat relapsing forms of MS.</p>









 <span class="anchor" id="tecfidera-vs-other-drugs"></span>
<!--[MMR]--><!--[END MMR]--><h2>Tecfidera vs. other drugs</h2>









<p>You may wonder how Tecfidera compares to other medications that are prescribed for similar uses. Below are comparisons between Tecfidera and several medications.</p>









<h3>Tecfidera vs. Aubagio</h3>









<p>Tecfidera and Aubagio (teriflunomide) are both classified as disease-modifying therapies. They both decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and Aubagio are both FDA-approved for treating relapsing forms of multiple sclerosis (MS).</p>









<p><strong>Drug forms</strong></p>









<p>Tecfidera comes as a delayed-release oral capsule that's taken twice daily. Aubagio comes as an oral tablet that's taken once daily.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and Aubagio have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td></td>









<td><strong>Both Tecfidera and Aubagio</strong></td>









<td><strong>Tecfidera</strong></td>









<td><strong>Aubagio</strong></td>









</tr>
<tr>
<td style="text-align: left;"><strong>More common side effects</strong></td>









<td>
<ul>
<li style="text-align: left;">diarrhea</li>









<li style="text-align: left;">nausea</li>









</ul>
</td>









<td>
<ul>
<li style="text-align: left;">flushing</li>









<li style="text-align: left;">stomach pain</li>









<li style="text-align: left;">vomiting</li>









<li style="text-align: left;">stomach upset</li>









<li style="text-align: left;">itchy skin</li>









<li style="text-align: left;">rash</li>









</ul>
</td>









<td>
<ul>
<li style="text-align: left;">headache</li>









<li style="text-align: left;">hair loss</li>









<li style="text-align: left;">joint pain</li>









</ul>
</td>









</tr>
<tr>
<td style="text-align: left;"><strong>Serious side effects</strong></td>









<td>
<ul>
<li style="text-align: left;">liver damage</li>









<li style="text-align: left;">severe allergy</li>









</ul>
</td>









<td>
<ul>
<li style="text-align: left;">brain infection (PML)</li>









<li style="text-align: left;">low white blood cell levels (lymphopenia)</li>









<li style="text-align: left;">serious flushing</li>









</ul>
</td>









<td>
<ul>
<li style="text-align: left;">severe infection</li>









<li style="text-align: left;">severe skin reactions</li>









<li style="text-align: left;">nerve damage</li>









<li style="text-align: left;">increased <a href="/articles/270644.php" title="What is a normal blood pressure?" class="keywords">blood pressure</a>
</li>









<li style="text-align: left;">lung damage</li>









<li style="text-align: left;">
<strong>boxed warnings:</strong>* serious liver damage, fetal harm</li>









</ul>
</td>









</tr>
</tbody></table>
<p><em>* <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155" target="_blank" rel="noopener">Aubagio</a> has <a href="https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf" target="_blank" rel="noopener">boxed warnings</a> from the FDA. These are the strongest warning that the FDA requires. A boxed warning alerts doctors and patients about drug effects that may be dangerous.</em></p>









<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and Aubagio are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, in one <a href="https://www.msard-journal.com/article/S2211-0348(16)30193-6/fulltext" target="_blank" rel="noopener">analysis</a>, they were compared indirectly and were found to have similar benefits.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera and Aubagio are only available as brand-name drugs. Generic versions of these drugs aren't available. Generic forms are typically less expensive than brand-name drugs.</p>









<p>Tecfidera generally costs a little bit more than Aubagio. However, the exact price you pay will depend on your insurance plan.</p>









<h3>Tecfidera vs. Copaxone</h3>









<p>Tecfidera and Copaxone (glatiramer acetate) are both classified as disease-modifying therapies. They both decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and Copaxone are both FDA-approved for treating relapsing forms of multiple sclerosis (MS).</p>









<p><strong>Drug forms</strong></p>









<p>One advantage of Tecfidera is that it's taken by mouth. It comes as a delayed-release oral capsule that's taken twice daily.</p>









<p>Copaxone must be injected. It comes as a self-injectable subcutaneous injection. It can be given at home either once daily or three times per week.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and Copaxone have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td style="width: 125px;"></td>









<td style="width: 139px;"><strong>Both Tecfidera and Copaxone</strong></td>









<td style="width: 190px;"><strong>Tecfidera</strong></td>









<td style="width: 184px;"><strong>Copaxone</strong></td>









</tr>
<tr>
<td style="text-align: left; width: 125px;"><strong>More common side effects</strong></td>









<td style="width: 139px;">
<ul>
<li style="text-align: left;">nausea</li>









<li style="text-align: left;">vomiting</li>









<li style="text-align: left;">rash</li>









<li style="text-align: left;">itchy skin</li>









</ul>
</td>









<td style="width: 190px;">
<ul>
<li style="text-align: left;">flushing</li>









<li style="text-align: left;">stomach pain</li>









<li style="text-align: left;">stomach upset</li>









<li style="text-align: left;">diarrhea</li>









</ul>
</td>









<td style="width: 184px;">
<ul>
<li style="text-align: left;">palpitations</li>









<li style="text-align: left;">fast heartbeat</li>









<li style="text-align: left;">vision problems</li>









<li style="text-align: left;">trouble swallowing</li>









<li style="text-align: left;">injection site pain, redness, and itching</li>









<li style="text-align: left;">weakness</li>









<li style="text-align: left;">fever</li>









<li style="text-align: left;">chills</li>









<li style="text-align: left;"><a href="/articles/187978.php" title="What to know about water retention" class="keywords">fluid retention</a></li>









<li style="text-align: left;">respiratory infections</li>









<li style="text-align: left;"><a href="/articles/172943.php" title="What is causing this pain in my back?" class="keywords">back pain</a></li>









<li style="text-align: left;"><a href="/info/anxiety/" title="What is Anxiety?" class="keywords">anxiety</a></li>









<li style="text-align: left;">shortness of breath</li>









</ul>
</td>









</tr>
<tr>
<td style="width: 125px; text-align: left;"><strong>Serious side effects</strong></td>









<td style="width: 139px; text-align: left;"><em>(few similar serious side effects)</em></td>









<td style="width: 190px; text-align: left;">
<ul>
<li>brain infection (PML)</li>









<li>low white blood cell levels (lymphopenia)</li>









<li>serious flushing</li>









<li>liver damage</li>









<li>severe allergy</li>









</ul>
</td>









<td style="width: 184px; text-align: left;">
<ul>
<li>severe injection reaction</li>









<li>chest pain</li>









</ul>
</td>









</tr>
</tbody></table>
<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and Copaxone are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, according to one <a href="https://www.futuremedicine.com/doi/10.2217/cer-2016-0085" target="_blank" rel="noopener">analysis</a>, Tecfidera may be more effective than Copaxone for preventing relapse and slowing worsening of disability.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera is only available as a brand-name drug. Copaxone is available as a brand-name drug. It's also available in a generic form called glatiramer acetate.</p>









<p>The generic form of Copaxone is much less expensive than Tecfidera. Brand-name Copaxone and Tecfidera generally cost about the same. The actual amount you pay will depend on your insurance plan.</p>









<h3>Tecfidera vs. Ocrevus</h3>









<p>Tecfidera and Ocrevus (ocrelizumab) are both classified as disease-modifying therapies. Both decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and Ocrevus are both FDA-approved for treating relapsing forms of multiple sclerosis (MS). Ocrevus is also approved for treating progressive forms of MS.</p>









<p><strong>Drug forms</strong></p>









<p>An advantage of Tecfidera is that it can be taken by mouth. It comes as a delayed-release oral capsule that's taken twice daily.</p>









<p>Ocrevus must be injected using an intravenous (IV) infusion. It must be administered in a clinic or hospital. After the first two doses, Ocrevus is given every six months.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and Ocrevus have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td></td>









<td><strong>Both Tecfidera and Ocrevus</strong></td>









<td><strong>Tecfidera</strong></td>









<td><strong>Ocrevus</strong></td>









</tr>
<tr>
<td style="text-align: left;"><strong>More common side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>diarrhea</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>flushing</li>









<li>stomach pain</li>









<li>nausea</li>









<li>vomiting</li>









<li>stomach upset</li>









<li>itchy skin</li>









<li>rash</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>depression</li>









<li>respiratory infections</li>









<li>back pain</li>









<li>
<a href="/articles/151739.php" title="Symptoms, causes, and treatment for herpes" class="keywords">herpes</a> infections (if exposed to the virus)</li>









<li>pain in arms and legs</li>









<li>cough</li>









<li>swelling in legs</li>









<li>skin infection</li>









</ul>
</td>









</tr>
<tr>
<td style="text-align: left;"><strong>Serious side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>brain infection (PML)</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>low white blood cell levels (lymphopenia)</li>









<li>serious flushing</li>









<li>liver damage</li>









<li>severe allergy</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>severe infusion reaction</li>









<li>cancer</li>









<li>severe infections</li>









<li>
<a href="/articles/306288.php" title="Everything you need to know about hepatitis B" class="keywords">hepatitis B</a> reactivation</li>









</ul>
</td>









</tr>
</tbody></table>
<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and Ocrevus are effective for treating MS, but it's not clear if one works better than the other. The effectiveness of these drugs hasn't been directly compared in clinical studies.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera and Ocrevus are available as brand-name medications. They're not available in generic forms, which can be less expensive than brand-name drugs.</p>









<p>Ocrevus may cost less than Tecfidera. The actual amount you pay will depend on your insurance plan.</p>









<h3>Tecfidera vs. Tysabri</h3>









<div id="middle-of-article"></div>
<p>Tecfidera and Tysabri (natalizumab) are both classified as disease-modifying therapies. Both drugs decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and Tysabri are both FDA-approved for treating relapsing forms of multiple sclerosis (MS). Tysabri is also approved for treating <a href="/articles/151620.php" title="What is Crohn's disease?" class="keywords">Crohn's disease</a>.</p>









<p><strong>Drug forms</strong></p>









<p>One advantage of Tecfidera is that it's taken by mouth. Tecfidera comes as a delayed-release oral capsule that's taken twice daily.</p>









<p>Tysabri must be administered as an intravenous (IV) infusion that's given in a clinic or hospital. It's given once every month.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and Tysabri have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td></td>









<td><strong>Both Tecfidera and Tysabri</strong></td>









<td><strong>Tecfidera</strong></td>









<td><strong>Tysabri</strong></td>









</tr>
<tr>
<td style="text-align: left;"><strong>More common side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>rash</li>









<li>itchy skin</li>









<li>diarrhea</li>









<li>stomach upset</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>flushing</li>









<li>stomach pain</li>









<li>nausea</li>









<li>vomiting</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>headache</li>









<li>fatigue</li>









<li>joint pain</li>









<li>weight loss or gain</li>









<li>urinary tract infection</li>









<li>vaginal infection</li>









<li>respiratory infection</li>









<li>flu-like symptoms</li>









<li>stomach infection</li>









<li>depression</li>









<li>pain in arms and legs</li>









<li><a href="/knowledge/160900/vertigo-causes-symptoms-treatments" title="Everything you need to know about vertigo" class="keywords">vertigo</a></li>









<li>irregular menstruation</li>









<li>constipation</li>









</ul>
</td>









</tr>
<tr>
<td style="text-align: left;"><strong>Serious side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>brain infection (PML)*</li>









<li>liver damage</li>









<li>severe allergy</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>low white blood cell levels (lymphopenia)</li>









<li>serious flushing</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>life-threatening herpes infection (if exposed to the virus)</li>









<li>serious infections</li>









</ul>
</td>









</tr>
</tbody></table>
<p><em>* Both of these drugs have been linked with progressive multifocal leukoencephalopathy (PML), but only <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962" target="_blank" rel="noopener">Tysabri</a> has a related <a href="https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf" target="_blank" rel="noopener">boxed warning</a> from the FDA. This is the strongest warning the FDA requires. A boxed warning alerts doctors and patients about drug effects that may be dangerous.</em></p>









<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and Tysabri are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, according to one <a href="https://www.tandfonline.com/doi/abs/10.1185/03007995.2013.863755?journalCode=icmo20" target="_blank" rel="noopener">analysis</a>, Tysabri may be more effective than Tecfidera for preventing relapse.</p>









<p>It's important to note that due to its risk of PML, Tysabri is usually not a first-choice medication for MS.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera and Tysabri are only available as brand-name drugs. Generic versions of these drugs aren't available. Generics typically cost less than brand-name medications.</p>









<p>Tecfidera generally costs more than Tysabri. The actual amount you pay will depend on your insurance plan.</p>









<h3>Tecfidera vs. Gilenya</h3>









<p>Tecfidera and Gilenya (fingolimod) are both classified as disease-modifying therapies. Both decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and Gilenya are both FDA-approved for treating relapsing forms of multiple sclerosis (MS).</p>









<p><strong>Drug forms</strong></p>









<p>Tecfidera comes as a delayed-release oral capsule that's taken twice daily. Gilenya comes as an oral capsule that's taken once daily.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and Gilenya have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td></td>









<td><strong>Both Tecfidera and Gilenya</strong></td>









<td><strong>Tecfidera</strong></td>









<td><strong>Gilenya</strong></td>









</tr>
<tr>
<td style="text-align: left;"><strong>More common side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>diarrhea</li>









<li>nausea</li>









<li>stomach pain</li>









<li>stomach upset</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>flushing</li>









<li>vomiting</li>









<li>itchy skin</li>









<li>rash</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>respiratory infections such as flu or <a href="/articles/8888.php" title="Symptoms and treatment of bronchitis" class="keywords">bronchitis</a>
</li>









<li>shingles</li>









<li>headache</li>









<li>weakness</li>









<li>pain in the back or arms and legs</li>









<li>hair loss</li>









<li>cough</li>









<li>vision problems</li>









</ul>
</td>









</tr>
<tr>
<td style="text-align: left;"><strong>Serious side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>brain infection (PML)</li>









<li>liver damage</li>









<li>severe allergy</li>









<li>low white blood cell levels (lymphopenia)</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>serious flushing</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>abnormal heartbeat or slow heart rate</li>









<li>severe herpes infection (if exposed to the virus)</li>









<li>serious infections</li>









<li>reduced lung function</li>









<li>fluid in the eye (macular <a href="/articles/159111.php" title="Everything you need to know about edema" class="keywords">edema</a>)</li>









<li>brain disorder (posterior reversible encephalopathy syndrome)</li>









<li>increased blood pressure</li>









<li><a href="/articles/154322.php" title="What you should know about melanoma" class="keywords">skin cancer</a></li>









<li><a href="/articles/146136.php" title="What to know about lymphoma" class="keywords">lymphoma</a></li>









<li>seizures</li>









</ul>
</td>









</tr>
</tbody></table>
<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and Gilenya are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, according to one <a href="https://www.tandfonline.com/doi/abs/10.1185/03007995.2013.863755?journalCode=icmo20" target="_blank" rel="noopener">analysis</a>, Tecfidera and Gilenya work about equally well for preventing relapse.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera and Gilenya are only available as brand-name drugs. Generic versions of these drugs aren't available. Generics typically cost less than brand-name medications.</p>









<p>Tecfidera and Gilenya generally cost about the same. The actual amount you pay will depend on your insurance plan.</p>









<h3>Tecfidera vs. interferon (Avonex, Rebif)</h3>









<p>Tecfidera and interferon (Avonex, Rebif) are both classified as disease-modifying therapies. Both decrease certain immune functions of the body, but they work in different ways.</p>









<p><strong>Uses</strong></p>









<p>Tecfidera and interferon (Avonex, Rebif) are each FDA-approved for treating relapsing forms of multiple sclerosis (MS).</p>









<p><strong>Drug forms</strong></p>









<p>One advantage of Tecfidera is that it's taken by mouth. Tecfidera comes as a delayed-release oral capsule that's taken twice daily.</p>









<p>Avonex and Rebif are two different brand names of interferon beta-1a. Both forms must be injected. Rebif comes as a subcutaneous injection that's given under the skin three times per week. Avonex comes as an intramuscular injection that's given into a muscle once weekly. Both are self-administered at home.</p>









<p><strong>Side effects and risks</strong></p>









<p>Tecfidera and interferon have some similar side effects and some that differ. Below are examples of these side effects.</p>









<table><tbody>
<tr>
<td></td>









<td><strong>Both Tecfidera and interferon</strong></td>









<td><strong>Tecfidera</strong></td>









<td><strong>Interferon</strong></td>









</tr>
<tr>
<td style="text-align: left;"><strong>More common side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>rash</li>









<li>nausea</li>









<li>stomach pain</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>flushing</li>









<li>vomiting</li>









<li>stomach upset</li>









<li>itchy skin</li>









<li>diarrhea</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>injection site pain or irritation</li>









<li>flu-like symptoms</li>









<li>respiratory infections</li>









<li>headache</li>









<li>fatigue</li>









<li>weakness</li>









<li>fever</li>









<li>chest pain</li>









<li>sleepiness</li>









<li>thyroid disorder</li>









<li>pain in the back, joints, or muscles</li>









<li>vision problems</li>









<li>dizziness</li>









<li>hair loss</li>









<li>urinary tract infections</li>









</ul>
</td>









</tr>
<tr>
<td style="text-align: left;"><strong>Serious side effects</strong></td>









<td style="text-align: left;">
<ul>
<li>liver damage</li>









<li>severe allergy</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>serious flushing</li>









<li>brain infection (PML)</li>









<li>low white blood cell levels (lymphopenia)</li>









</ul>
</td>









<td style="text-align: left;">
<ul>
<li>depression</li>









<li><a href="/kc/suicidal-thoughts-ideation-193026" title="What are suicidal thoughts?" class="keywords">suicidal thoughts</a></li>









<li>blood disorders</li>









<li>seizures</li>









<li><a href="/articles/156849.php" title="Congestive heart failure: What you need to know" class="keywords">heart failure</a></li>









</ul>
</td>









</tr>
</tbody></table>
<p><strong>Effectiveness</strong></p>









<p>Both Tecfidera and interferon are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, according to one <a href="https://www.tandfonline.com/doi/abs/10.1185/03007995.2013.863755?journalCode=icmo20" target="_blank" rel="noopener">analysis</a>, Tecfidera may be more effective than interferon for preventing relapse and slowing worsening of disability.</p>









<p><strong>Costs</strong></p>









<p>Tecfidera and interferon (Rebif, Avonex) are only available as brand-name drugs. Generic versions of these drugs aren't available. Generics typically cost less than brand-name medications.</p>









<p>Tecfidera and interferon generally cost about the same. The actual amount you pay will depend on your insurance.</p>









<h3>Tecfidera vs. Protandim</h3>









<p>Tecfidera is an FDA-approved drug for treating relapsing forms of multiple sclerosis (MS). Several clinical <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">studies</a> have shown that it can prevent MS relapse and slow worsening of physical disability.</p>









<p>Protandim is a dietary supplement that contains several ingredients, including:</p>









<ul>
<li>milk thistle</li>









<li>ashwagandha</li>









<li><a href="/articles/269538.php" title="Green tea: Health benefits, side effects, and research" class="keywords">green tea</a></li>









<li>turmeric</li>









<li>bacopa</li>









</ul>
<p>Some claim that Protandim works like Tecfidera works. Protandim is sometimes called a "natural Tecfidera."</p>









<p>However, Protandim has never been studied in people with MS. Therefore, there is no reliable clinical research that it works.</p>









<p>Note: If your doctor has prescribed Tecfidera for you, don't replace it with Protandim. If you would like to explore other treatment options, talk with your doctor.</p>









 <span class="anchor" id="dosage"></span>
<h2>Tecfidera dosage</h2>









<p>The following information describes dosages that are commonly used or recommended. <strong>However, be sure to take the dosage your doctor prescribes for you.</strong> Your doctor will determine the best dosage to suit your needs.</p>









<h3>Dosage for multiple sclerosis</h3>









<p>When Tecfidera is started, the dosage is 120 mg twice a day for the first seven days. After this first week, the dosage is increased to 240 mg twice daily. This is the long-term maintenance dose.</p>









<p>For people who have bothersome side effects from Tecfidera, the maintenance dosage can be temporarily decreased to 120 mg twice daily. The higher maintenance dosage of 240 mg twice daily should be started again within four weeks.</p>









<h3>What if I miss a dose?</h3>









<p>If you miss a dose, take it as soon as you remember. If it's almost time for your next dose, just take that one dose. Don't try to catch up by taking two doses at once.</p>









<h3>Will I need to use this drug long term?</h3>









<p>Yes, this medication is intended to be taken long term.</p>









 <span class="anchor" id="how-to-take"></span>
<h2>How to take Tecfidera</h2>









<p>Take Tecfidera exactly according to your doctor's instructions.</p>









<h3>Timing</h3>









<p>Tecfidera is taken twice daily. It's usually taken with the morning meal and the evening meal.</p>









<h3>Taking Tecfidera with food</h3>









<p>Tecfidera should be taken with food. This can help reduce the flushing side effect. Flushing can also be reduced by taking 325 mg of aspirin 30 minutes before taking Tecfidera.</p>









<h3>Can Tecfidera be crushed?</h3>









<p>Tecfidera shouldn't be crushed, or opened and sprinkled on food. Tecfidera capsules should be swallowed whole.</p>









 <span class="anchor" id="pregnancy"></span>
<!--[MMR]--><!--[END MMR]--><h2>Pregnancy and Tecfidera</h2>









<p>Animal studies show that Tecfidera may be harmful to a fetus and may not be safe to take during pregnancy. However, animal studies don't always predict what will happen in humans.</p>









<p>Studies haven't evaluated the effects of Tecfidera regarding pregnancy or birth defects in humans.</p>









<p>If you're pregnant or planning to become pregnant, talk with your doctor about whether you should take Tecfidera.</p>









<p>If you become pregnant while taking Tecfidera, you can take part in the Tecfidera Pregnancy Registry. A pregnancy registry helps gather information on how certain drugs can affect pregnancy. If you'd like to join the registry, ask your doctor, call 866-810-1462, or visit the registry's <a href="https://www.tecfiderapregnancyregistry.com/" target="_blank" rel="noopener">website</a>.</p>









 <span class="anchor" id="breastfeeding"></span>
<!--[DLB]--><div id="hl-incontent-video-ad"></div>
<div id="div-gpt-ad-out-of-page"></div>
<script type="text/javascript">
	googleAdSlotInfo.push({
		"slotName":'out-of-page',
		"slotContainer":'div-gpt-ad-out-of-page'	});
</script><!--[END DLB]--><h2>Breastfeeding and Tecfidera</h2>









<p>There haven't been enough studies to show whether Tecfidera appears in breast milk.</p>









<p>Some <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+1162" target="_blank" rel="noopener">experts</a> recommend avoiding breastfeeding while taking this drug. However, others don't. If you're taking Tecfidera and would like to breastfeed your child, talk with your doctor about the potential risks and benefits.</p>









 <span class="anchor" id="how-it-works"></span>
<div id="threequarter-of-article"></div>
<h2>How Tecfidera works</h2>









<p>Multiple sclerosis (MS) is an autoimmune disease. With this type of condition, the immune system, which fights disease, mistakes healthy cells for enemy invaders and attacks them. This can cause chronic <a href="/articles/248423.php" title="Everything you need to know about inflammation" class="keywords">inflammation</a>.</p>









<p>With MS, this chronic inflammation is thought to cause nerve damage, including the demyelination that causes many MS symptoms. Oxidative <a href="/articles/145855.php" title="Why stress happens and how to manage it" class="keywords">stress</a> (OS) is also thought to cause this damage. OS is an imbalance of certain molecules in your body.</p>









<p>Tecfidera is thought to help treat MS by causing the body to produce a protein called Nrf2. This protein is thought to help regain the body's molecular balance. This effect, in turn, helps reduce the damage caused by inflammation and OS.</p>









<p>In addition, Tecfidera changes some of the body's immune cell functions to decrease certain inflammatory responses. It may also prevent the body from activating certain immune cells. These effects could also help reduce MS symptoms.</p>









<h3>How long does it take to work?</h3>









<p>Tecfidera will begin to work in your body right away, but it can take several weeks to reach its full effect.</p>









<p>While it's working, you may not notice much improvement in your symptoms. This is because it's mainly intended to prevent relapses.</p>









 <span class="anchor" id="tecfidera-and-alcohol"></span>
<!--[MMR]--><!--[END MMR]--><h2>Tecfidera and alcohol</h2>









<p>Tecfidera doesn't interact with alcohol. However, alcohol might worsen certain side effects of Tecfidera, such as:</p>









<ul>
<li>diarrhea</li>









<li>nausea</li>









<li>flushing</li>









</ul>
<p>Avoid drinking excessive amounts of alcohol while taking Tecfidera.</p>









 <span class="anchor" id="interactions"></span>
<h2>Tecfidera interactions</h2>









<p>Tecfidera may interact with other medications. Below is a list of medications that may interact with Tecfidera. This list may not contain all drugs that may interact with Tecfidera.</p>









<p>Different drug interactions can cause different effects. For instance, some can interfere with how well a drug works, while others can cause increased side effects.</p>









<p>Before taking Tecfidera, be sure to tell your doctor and pharmacist about all prescription, over-the-counter, and other drugs you take. Also tell them about any <a href="/articles/195878.php" title="Vitamins: What are they and what do they do?" class="keywords">vitamins</a>, herbs, and supplements you use. Sharing this information can help you avoid potential interactions.</p>









<p>If you have questions about drug interactions that may affect you, ask your doctor or pharmacist.</p>









<h3>Tecfidera and ocrelizumab (Ocrevus)</h3>









<p>Taking Tecfidera with ocrelizumab can increase the risk of immunosuppression and resulting serious infections. Immunosuppression is when the immune system is weakened.</p>









<h3>Tecfidera and ibuprofen</h3>









<p>There are no known interactions between ibuprofen and Tecfidera.</p>









<h3>Tecfidera and aspirin</h3>









<p>There are no known interactions between aspirin and Tecfidera. Aspirin is commonly used 30 minutes before taking Tecfidera to prevent flushing.</p>









 <span class="anchor" id="common-questions"></span>
<h2>Common questions about Tecfidera</h2>









<p>Here are answers to some frequently asked questions about Tecfidera.</p>









<h3>Why does Tecfidera cause flushing?</h3>









<p>It's not exactly clear why Tecfidera causes flushing. However, it likely has to do with the dilation (widening) of blood vessels in the face where the flushing occurs.</p>









<h3>How can you prevent flushing from Tecfidera?</h3>









<p>You may not be able to entirely prevent flushing caused by Tecfidera, but there are two things you can do to help reduce it:</p>









<ul>
<li>Take Tecfidera with a meal.</li>









<li>Take 325 mg of aspirin 30 minutes before taking Tecfidera.</li>









</ul>
<p>If these steps don't help and you still have bothersome flushing, talk with your doctor.</p>









<h3>Does Tecfidera make you tired?</h3>









<p>Some people who take Tecfidera say they feel fatigue. However, feelings of tiredness or sleepiness are not side effects that have been found in clinical studies of Tecfidera.</p>









<h3>Is Tecfidera an immunosuppressant?</h3>









<p>Tecfidera does affect the immune system. It reduces some immune system functions to decrease inflammatory responses. It may also reduce activation of certain immune cells.</p>









<p>However, Tecfidera isn't usually categorized as an immunosuppressant. It's sometimes called an immunomodulator, which means that it affects some functions of the immune system.</p>









<h3>Do I need to worry about sun exposure while taking Tecfidera?</h3>









<p>Tecfidera doesn't make your skin more sensitive to the sun like some drugs do. However, if you experience flushing from Tecfidera, sun exposure could worsen the flushing feeling.</p>









<h3>How effective is Tecfidera?</h3>









<p>Tecfidera has been found to reduce MS relapse by up to <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">49 percent</a> over two years. It's also been found to reduce the risk of having worsening physical disability by about <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">38 percent</a>.</p>









<h3>Why do I have different dosing directions after the first week?</h3>









<p>It's common for medications to be started at a lower dosage and then increased later. This allows your body to process a lower dosage as it adjusts to the medication.</p>









<p>For Tecfidera, you start with a lower dosage of 120 mg twice daily during the first seven days. After that, the dosage is increased to 240 mg twice daily, and this is the dosage you would stay on. However, if you have too many side effects with the higher dosage, your doctor may lower your dosage for a time.</p>









<h3>Do I need to get blood tests while I'm on Tecfidera?</h3>









<p>Yes. Before you start taking Tecfidera, your doctor will do blood tests to check your blood cell counts and your liver function. These tests will likely be repeated during your treatment with the drug. For the first year of treatment, these tests are typically done at least every six months.</p>









 <span class="anchor" id="overdose"></span>
<!--[DLB]--><!-- Leaderboard BANNER advert -->

<div id="dlb3_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb3_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB3',
			"slotContainer":'dlb3_container'		});
	</script>
	</div>
	

</div>






<!-- /header_ad code --><!--[END DLB]--><!--[MMR]--><!--[END MMR]--><h2>Tecfidera overdose</h2>









<p>Taking too much of this medication can increase your risk of serious side effects.</p>









<h3>Overdose symptoms</h3>









<p>Symptoms of an overdose can include:</p>









<ul>
<li>diarrhea</li>









<li>nausea</li>









<li>flushing</li>









<li>vomiting</li>









<li>rash</li>









<li>upset stomach</li>









<li>headache</li>









</ul>
<h3>What to do in case of overdose</h3>









<p>If you think you've taken too much of this drug, call your doctor or seek guidance from the American Association of Poison Control Centers at 800-222-1222 or through their <a href="https://www.poisonhelp.org/help" target="_blank" rel="noopener">online tool</a>. <strong>But if your symptoms are severe, call 911 or go to the nearest emergency room right away.</strong></p>









 <span class="anchor" id="warnings"></span>
<h2>Warnings for Tecfidera</h2>









<p>Before taking Tecfidera, talk with your doctor about any medical conditions you have. Tecfidera may not be right for you if you have certain medical conditions. These conditions include:</p>









<ul>
<li>
<strong>Immune system suppression</strong>: If your immune system is suppressed, Tecfidera may worsen this condition. This effect can increase your risk of serious infections.</li>









<li>
<strong>Liver disease</strong>: Tecfidera can cause liver damage. If you already have liver disease, it may worsen your condition.</li>









</ul>
<span class="anchor" id="expiration"></span>
<h2>Tecfidera expiration</h2>









<p>When Tecfidera is dispensed from the pharmacy, the pharmacist will add an expiration date to the label on the bottle. This date is typically one year from the date the medication was dispensed.</p>









<p>The purpose of such expiration dates is to guarantee the effectiveness of the medication during this time. The <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm481139.htm" target="_blank" rel="noopener">current stance</a> of the Food and Drug Administration (FDA) is to avoid using expired medications. However, an FDA <a href="https://www.ncbi.nlm.nih.gov/pubmed/16721796?dopt=Abstract" target="_blank" rel="noopener">study</a> showed that many medications may still be good beyond the expiration date listed on the bottle.</p>









<p>How long a medication remains good can depend on many factors, including how and where the medication is stored. Tecfidera should be stored at room temperature in the original container and protected from light.</p>









<p>If you have unused medication that has gone past the expiration date, talk to your pharmacist about whether you might still be able to use it.</p>









 <span class="anchor" id="professional-information"></span>
<!--[MMR]--><!--[END MMR]--><h2>Professional information for Tecfidera</h2>









<p>The following information is provided for clinicians and other healthcare professionals.</p>









<h3>Mechanism of action</h3>









<p>The mechanism of action of Tecfidera is complex and not fully understood. It works for multiple sclerosis (MS) through anti-inflammatory effects and <a href="/articles/301506.php" title="How can antioxidants benefit our health?" class="keywords">antioxidant</a> effects. Inflammation and oxidative stress are thought to be important pathological processes in patients with MS.</p>









<p>Tecfidera induces the nuclear 1 factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant pathway, which protects against oxidative damage in the <a href="/articles/307076.php" title="All about the central nervous system" class="keywords">central nervous system</a> and reduces nerve demyelination.</p>









<p>Tecfidera also inhibits multiple immune pathways related to toll-like receptors, which reduces inflammatory cytokine production. Tecfidera also reduces activation of immune T-cells.</p>









<h3>Pharmacokinetics and metabolism</h3>









<p>After oral administration of Tecfidera, it's rapidly metabolized by esterases to its active metabolite, monomethyl fumarate (MMF). Therefore, dimethyl fumarate isn't quantifiable in the plasma.</p>









<p>The time to MMF maximum concentration (Tmax) is 2–2.5 hours.</p>









<p>Exhalation of carbon dioxide is responsible for elimination of 60 percent of the drug. Renal and fecal elimination are minor routes.</p>









<p>The half-life of MMF is about 1 hour.</p>









<h3>Contraindications</h3>









<p>Tecfidera is contraindicated in patients with a known hypersensitivity to dimethyl fumarate or any excipients.</p>









<h3>Storage</h3>









<p>Tecfidera should be stored at room temperature, 59°F to 86°F (15°C to 30°C). It should be stored in the original container and protected from light.</p>









<h3>Prescribing information</h3>









<p>The full Tecfidera prescribing information can be found <a href="https://www.tecfidera.com/content/dam/commercial/multiple-sclerosis/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf" target="_blank" rel="noopener">here</a>.</p>









<p><strong>Disclaimer</strong>: MedicalNewsToday has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.</p>
<div id="bottom-of-article"></div>
 	</div> 	</div> 
<style type="text/css">
		/*.mnt_dlb_foot_container { display:block; width: 728px; height: 90px; }*/
		/*@media (min-width: 990px) { .mnt_dlb_foot_container { display: none; } }
		@media (min-width:1148px) { .mnt_dlb_foot_container { display:block;} }*/
</style>
<!-- MNT_Adsense_Desktop_728x90 Footer -->
<ins class="adsbygoogle mnt_dlb_foot_container"
	 id="mnt_dlb_foot_container"
     style="display:inline-block;width:728px;height:90px"
     data-ad-client="ca-pub-4771166113579725"
     data-ad-slot="9436500920"></ins>


<script>


	fireOrSaveJsFunctions(1,function(){loadScript(
		"//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js",
		{},
		function(){}

	)});


</script>
<script>(adsbygoogle = window.adsbygoogle || []).push({});</script>



<p id='slidebox_trigger'></p>

	<div id="suggest_reading_outer_container" class="place full">

		<h2 class="suggested_reading internal_related">Related coverage</h2>
	<span></span>
		<!--<h2 class="suggested_reading">Suggested Reading</h2>-->
	
	<div itemscope itemtype="http://schema.org/WebPage"> <!-- suggested_reading_container_parent -->
	<div class="suggested_reading_container ">
				<div class='suggested_reading_inner column1'>
				<div class="suggested_item">
		<a href="/articles/325462.php" title="What to know about surgery for MS" class="related_coverage_link" data-id="325462">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/325/325462/325462_1100.jpg" alt="" />
		</div>
				<span class="title">What to know about surgery for MS</span>
		<span class="summary">In some cases, multiple sclerosis (MS) can respond to certain types of surgery, which may include deep brain stimulation. Many other surgical treatments are available that can also help reduce symptoms. Learn more here.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column2'>
				<div class="suggested_item">
		<a href="/articles/315227.php" title="Multiple sclerosis (MS) diet tips" class="related_coverage_link" data-id="315227">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/315/315227/315227_1100.jpg" alt="" />
		</div>
				<span class="title">Multiple sclerosis (MS) diet tips</span>
		<span class="summary">Multiple sclerosis, or MS, is a chronic condition that can lead to weakness and memory loss, among other symptoms. Some studies suggest that boosting the health of the gut flora by making dietary changes could improve symptoms. Find out which foods to eat, which to avoid, and which lifestyle changes can help.  </span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column3'>
				<div class="suggested_item">
		<a href="/articles/325455.php" title="Can naltrexone help with multiple sclerosis (MS)?" class="related_coverage_link" data-id="325455">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/325/325455/325455_1100.jpg" alt="" />
		</div>
				<span class="title">Can naltrexone help with multiple sclerosis (MS)?</span>
		<span class="summary">Low doses of naltrexone are a recent, popular treatment for MS symptoms. In this article, we look at the research, action, and side effects of naltrexone for MS. </span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column4'>
				<div class="suggested_item">
		<a href="/articles/325473.php" title="What to know about steroids and MS" class="related_coverage_link" data-id="325473">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/325/325473/325473_1100.jpg" alt="" />
		</div>
				<span class="title">What to know about steroids and MS</span>
		<span class="summary">Treatment options for multiple sclerosis (MS) flares include steroids. These can help reduce symptoms such as visual disturbances and weakness. Their effectiveness is relatively high. Learn more about steroids for MS here.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
				</div>
	</div>
	</div>
	

<div id="social_bottom"  >			
    <div id="share_social_bottom">    
        <div id="article_social_bottom_facebook" ></div>
        <div id="article_social_bottom_twitter" ></div>
        <div id="article_social_bottom_linkedin" ></div>

		    
    </div>
    <div class="toolbox">
		<div class="email">            <a rel="nofollow" title="email this article" href="#">
			<span class="toolbox_label">email</span></a>
            <span class="visuallyhidden">
            <a rel="nofollow" title="email this article" href="#">email</a>
            </span>
        </div>        
		        <div class="print">			            <a id="9e6c1bdba29462fdcae19f74074211f7" href="#" rel="nofollow" title="View print preview" target="_blank">
			<span class="toolbox_label">print</span></a>
        </div>        		
		<div class="share">            <a rel="nofollow" title="share this article" href="#">
			<span class="toolbox_label">share</span></a>
            <span class="visuallyhidden">
            <a rel="nofollow" title="share this article" href="#">share</a>
            </span>
        </div>

    </div>

</div><a id="rate-this-article"></a>	<div class="article_category_container">
					<div class="article_main_category_container"> 
				<span itemprop="genre" class="category_main">
				<a href="/categories/multiple_sclerosis" title="Multiple Sclerosis News" class="current">Multiple Sclerosis</a>
				</span>
			</div> 					<div class="article_sub_category_container">
					<span itemprop="genre" class="category_sub">
			<a href="/categories/pharmacy" title="Pharmacy / Pharmacist News" class="current">Pharmacy / Pharmacist</a>
			</span>
					</div> 	</div> 	                    <div class="widget_citation_group" id="widget_citation">

                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading active">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#additional">
                                        Additional information</a>
                                </h4>
                            </div>
                            <div id="additional" class="panel-collapse collapse in">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="additional" >

		<p> Article last reviewed by Thu 27 September 2018.<br><br>Visit our <a href='/categories/multiple_sclerosis' title='Visit our Multiple Sclerosis category page'>Multiple Sclerosis</a> category page for the latest news on this subject, or <a href='/newsletter' title='Sign up to our newsletter'>sign up to our newsletter</a> to receive the latest updates on Multiple Sclerosis.<br><br>All references are available in the <b>References</b> tab.		</p>
	</ul>
	                                </div>
                            </div>
                        </div>


                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#references">
                                        References</a>
                                </h4>
                            </div>
                            <div id="references" class="panel-collapse collapse">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="references" >
		<noscript> 
		This content requires JavaScript to be enabled.<br/><br/> 
		</noscript>
		<p>
		<p>Al-Jaderi, Z., <em>et al.</em> (2016). Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956641/" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956641/</a></p>
<p>Amato, M. P., <em>et al.</em> (2015). Fertility, pregnancy and childbirth in patients with multiple sclerosis. <a href="https://link.springer.com/article/10.1007%2Fs40263-015-0238-y" target="_blank" rel="noopener">https://link.springer.com/article/10.1007%2Fs40263-015-0238-y</a></p>
<p>Applebaum, B. (2015). Natural supplement Protandim claims to improve MS symptoms. <a href="http://moderndayms.com/2015/09/natural-supplement-protandim-claims-to-improve-ms-symptoms/" target="_blank" rel="noopener">http://moderndayms.com/2015/09/natural-supplement-protandim-claims-to-improve-ms-symptoms/</a></p>
<p>Aubagio - teriflunomide tablet, film coated. (2017). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155</a></p>
<p>Avonex - interferon beta-1a; Avonex Pen - interferon beta-1a injection, solution; Avonex - interferon beta-1a injection, solution; Avonex - interferon beta-1a injection, powder, lyophilized, for solution. (2017). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1</a></p>
<p>Bernardini, L. R., <em>et al.</em> (2016). Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis [Abstract]. <a href="https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(16)30439-7" target="_blank" rel="noopener">https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(16)30439-7</a></p>
<p>Chan, A., <em>et al.</em> (2017). Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: Results of a matching-adjusted indirect comparison. <a href="https://www.futuremedicine.com/doi/10.2217/cer-2016-0085?" target="_blank" rel="noopener">https://www.futuremedicine.com/doi/10.2217/cer-2016-0085?</a></p>
<p>Clinical pharmacology. (2018). Tampa, FL: Elsevier. <a href="http://www.clinicalpharmacology-ip.com/" target="_blank" rel="noopener">http://www.clinicalpharmacology-ip.com/</a></p>
<p>Copaxone - glatiramer acetate injection, solution. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357</a></p>
<p>FDA drug safety communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate). (2014). <a href="https://www.fda.gov/Drugs/DrugSafety/ucm424625.htm" target="_blank" rel="noopener">https://www.fda.gov/Drugs/DrugSafety/ucm424625.htm</a></p>
<p>Fernández, Ó., <em>et al.</em> (2017). Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: An integrated analysis of DEFINE and CONFIRM. <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext" target="_blank" rel="noopener">https://www.clinicaltherapeutics.com/article/S0149-2918(17)30765-8/fulltext</a></p>
<p>Freedman, M. S., <em>et al.</em> (2016). Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number of needed to treat analysis. <a href="https://www.msard-journal.com/article/S2211-0348(16)30193-6/fulltext" target="_blank" rel="noopener">https://www.msard-journal.com/article/S2211-0348(16)30193-6/fulltext</a></p>
<p>Gilenya - fingolimod hcl capsule. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9</a></p>
<p>Gold, R., <em>et al.</em> (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <a href="https://www.nejm.org/doi/10.1056/NEJMoa1114287?" target="_blank" rel="noopener">https://www.nejm.org/doi/10.1056/NEJMoa1114287?</a></p>
<p>Gold, R., <em>et al.</em> (2016). Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919132/" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919132/</a></p>
<p>Gold, R., <em>et al.</em> (2017). Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418934/" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418934/</a></p>
<p>GoodRx. (n.d.). <a href="https://www.goodrx.com/" target="_blank" rel="noopener">https://www.goodrx.com/</a></p>
<p>A guide to drug safety terms at FDA. (2012). <a href="https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf" target="_blank" rel="noopener">https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf</a></p>
<p>Hutchinson, M., <em>et al.</em> (2014). Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: A systematic review and mixed treatment comparison [Abstract]. <a href="https://www.tandfonline.com/doi/abs/10.1185/03007995.2013.863755?journalCode=icmo20" target="_blank" rel="noopener">https://www.tandfonline.com/doi/abs/10.1185/03007995.2013.863755?journalCode=icmo20</a></p>
<p>Kegel, M. (2016). How Tecfidera works to reduce MS relapses finally discovered, may lead to better treatments. <a href="https://multiplesclerosisnewstoday.com/2016/09/27/how-tecfidera-works-in-relapsing-multiple-sclerosis-discovered-insights-make-new-treatments-possible" target="_blank" rel="noopener">https://multiplesclerosisnewstoday.com/2016/09/27/how-tecfidera-works-in-relapsing-multiple-sclerosis-discovered-insights-make-new-treatments-possible</a></p>
<p>LactMed: Dimethyl fumarate. (n.d.). <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+1162" target="_blank" rel="noopener">http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+1162</a></p>
<p>Losavio, F. A., <em>et al.</em> (2016). Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. <a href="https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(16)30025-6" target="_blank" rel="noopener">https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(16)30025-6</a></p>
<p>Ma, B. B., <em>et al.</em> (2016). Disseminated zoster with paresis in a multiple sclerosis patients treated with dimethyl fumarate. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794808/" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794808/</a></p>
<p>Makhani, N., <em>et al.</em> (2016). Oral dimethyl fumarate in children with multiple sclerosis: A dual-center study [Abstract]. <a href="https://www.researchgate.net/publication/291387192_Oral_Dimethyl_Fumarate_in_Children_With_Multiple_Sclerosis_A_Dual-Center_Study" target="_blank" rel="noopener">https://www.researchgate.net/publication/291387192_Oral_Dimethyl_Fumarate_in_Children_With_Multiple_Sclerosis_A_Dual-Center_Study</a></p>
<p>Medications. (n.d.). <a href="https://www.nationalmssociety.org/Treating-MS/Medications" target="_blank" rel="noopener">https://www.nationalmssociety.org/Treating-MS/Medications</a></p>
<p>MS Coalition. (2017). The use of disease-modifying therapies in multiple sclerosis: Principles and current evidence. <a href="https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf" target="_blank" rel="noopener">https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf</a></p>
<p>Ocrevus - ocrelizumab injection. (2017). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d</a></p>
<p>Rae-Grant, A., <em>et al.</em> (2018). Practice guideline: Disease-modifying therapies for adults with multiple sclerosis. <a href="https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf" target="_blank" rel="noopener">https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf</a></p>
<p>Rebif - interferon beta-1a; Rebif Rebidose - interferon beta-1a; Rebif - interferon beta-1a injection, solution; Rebif Rebidose - interferon beta-1a injection solution. (2015). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f</a></p>
<p>Tecfidera - dimethyl fumarate; Tecfidera - dimethyl fumarate capsule. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151</a></p>
<p>Tysabri - natalizumab injection. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962</a></p>
<p>Xu, Z., <em>et al.</em> (2015). Dimethyl fumarate for multiple sclerosis [Abstract]. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25900414" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pubmed/25900414</a></p>		</p>
	</ul>
	                                </div>
                            </div>
                        </div>


                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#citations">
                                        Citations</a>
                                </h4>
                            </div>
                            <div id="citations" class="panel-collapse collapse">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="citations" >
		<p>Please use one of the following formats to cite this article in your essay, paper or report:</p><p><strong>MLA</strong><br />Network, MNT’s Medical. "Tecfidera (dimethyl fumarate)." <i>Medical News Today</i>. MediLexicon, Intl., 31 Aug. 2019. Web.<br>6 Sep. 2019. &lt;https://www.medicalnewstoday.com/articles/325954.php&gt;</p><hr size="1" /><p><strong>APA</strong><br />Network, M. (2019, August 31). "Tecfidera (dimethyl fumarate)." <i>Medical News Today</i>. Retrieved from<br><a href='https://www.medicalnewstoday.com/articles/325954.php' itemprop='url'>https://www.medicalnewstoday.com/articles/325954.php</a>.</p><hr size="1" /><p>Please note: If no author information is provided, the source is cited instead.</p>	</ul>
	                                </div>
                            </div>
                        </div>

                    </div>


					
	<hr class="nonprint"/>
<div class="article_email">
	<div id="header_close_button" class="email_close"></div>
	<div class="emailform_container">

	</div>
</div></div>  
</article>

	<div class="col-xs-12 col-sm-12 col-md-4 col-lg-4 sidebar"> 
<!-- article_ad code -->
<!-- MREC ARTICLE advert -->
<div id="dmr1_container" class="mnt css_hs211">

<div class="mnt_history" style="display:none;">
	<a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_knowledge_center_001.png" alt="MNT Knowledge Center" /></a>
 	

</div>

		<div id='dmr1_unit' adonis-marker>
		<script type='text/javascript'>
			googleAdSlotInfo.push({
				"slotName":'DMR1',
				"slotContainer":'dmr1_container'			});
		</script>
		</div>
		<span class='bt-uid-tg' data-uid='5b84643d24-160' style='display: none !important'></span></div> <!-- /article_ad code -->
	<div id="sidebar_feature" class="full">
			<h2>Latest news</h2>
		<span></span>
	<ul class="sidebar_feature">
	<li>	<a href="/articles/326281.php" title="Curiosities of medical history: Trepanation">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326281/326281_1100.jpg" alt="Curiosities of medical history: Trepanation" class="original">
	<div class="headline">Curiosities of medical history: Trepanation</div> 
	<div class="excerpt">Trepanation is the historical practice of drilling holes into the skull. But why did our ancestors do it, and when did it start? We investigate.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326278.php" title="Scientists identify genetic components of left-handedness">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326278/326278_1100.jpg" alt="Scientists identify genetic components of left-handedness" class="original">
	<div class="headline">Scientists identify genetic components of left-handedness</div> 
	<div class="excerpt">In a genetic analysis of 400,000 people, scientists have, for the first time, identified four DNA regions associated with left-handedness.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326243.php" title="World first: Doctors use 'reprogrammed' stem cells to repair cornea">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326243/326243_1100.jpg" alt="World first: Doctors use 'reprogrammed' stem cells to repair cornea" class="original">
	<div class="headline">World first: Doctors use 'reprogrammed' stem cells to repair cornea</div> 
	<div class="excerpt">In a groundbreaking procedure, surgeons have successfully repaired a human cornea using 'reprogrammed' cells from the patient's skin. </div>
	</div>

	</a></li>
	<li>	<a href="/articles/326232.php" title="Inflammation in late teens linked to mortality risk decades later">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326232/326232_1100.jpg" alt="Inflammation in late teens linked to mortality risk decades later" class="original">
	<div class="headline">Inflammation in late teens linked to mortality risk decades later</div> 
	<div class="excerpt">Experts know little about how inflammation in early life affects health later on. A new study links teen inflammation to mortality risk 35 years later.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326271.php" title="Scientists identify a trigger for type 1 diabetes in mice">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326271/326271_1100.jpg" alt="Scientists identify a trigger for type 1 diabetes in mice" class="original">
	<div class="headline">Scientists identify a trigger for type 1 diabetes in mice</div> 
	<div class="excerpt">Scientists discover a previously unknown switch that causes immune cells to begin destroying insulin, resulting in the onset of type 1 diabetes. </div>
	</div>

	</a></li>
		</ul>
	</div>
		<!-- article_ad code -->
<!-- MREC ARTICLE advert -->
<div id="dmr2_container" class="mnt css_hs211">

<div class="mnt_history" style="display:none;">
	<a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_knowledge_center_001.png" alt="MNT Knowledge Center" /></a>
 	

</div>

		<div id='dmr2_unit' adonis-marker>
		<script type='text/javascript'>
			googleAdSlotInfo.push({
				"slotName":'DMR2',
				"slotContainer":'dmr2_container'			});
		</script>
		</div>
		<span class='bt-uid-tg' data-uid='5b846454f2-160' style='display: none !important'></span></div> <!-- /article_ad code -->
	<div class="full popular_tabs_container"> 	<div class="full popular_tabs_parent"> 	<h2 class="popular_tabs_heading"><span>Popular in: </span>Multiple Sclerosis</h2><span></span>
	<div id="popular_tabs">
	<div class="centered">
	
	<ul class="nav">
		</ul>
	
			<div class="list-wrap">
					<ul id="popular-read">
				<li class="knowledge">
	<a href="/articles/323840.php" title="What is the difference between multiple sclerosis and fibromyalgia?">
		<span class="headline">
	What is the difference between multiple sclerosis and fibromyalgia?	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/324944.php" title="Signs and symptoms of MS in women">
		<span class="headline">
	Signs and symptoms of MS in women	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/323838.php" title="What to know about itching and MS">
		<span class="headline">
	What to know about itching and MS	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/323130.php" title="What are the early signs of MS?">
		<span class="headline">
	What are the early signs of MS?	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/323976.php" title="What do brain lesions mean in multiple sclerosis?">
		<span class="headline">
	What do brain lesions mean in multiple sclerosis?	</span>
		</a></li>
				<span></span> 			</ul>
					</div> <!-- /list_wrap -->
			</div> <!-- /the_tabs -->
	</div> <!-- /centered -->
	</div> 	</div> 	</div> <!-- /sidebar -->
</div> 
</div> 


	<img height="1" width="1" src="https://d.turn.com/r/dd/id/L21rdC84MTYvY2lkLzE3NDc2NjAwNjEvdC8y/kv/CampaignID=MedicalNewsToday,Content=ms">

<div id="message"><a href="#top" style="display: none;">Scroll to top</a></div>


<footer>

<div class="container">

	<div class="row"> 	
		<div class="col-xs-12 col-sm-12 col-md-12 col-lg-12 footer"> 		
			<div id="footer_logo">
				<a href="/"  title="Medical News Today : Home">
					<img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-mini-2017.png" alt="MNT home">
				</a>
			</div> 				
			<div id="footer_social">
				<span class="footer_facebook fa-stack fa-lg">
				<a href="https://www.facebook.com/MedicalNewsToday" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-facebook fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_twitter fa-stack fa-lg">
				<a href="https://twitter.com/mnt" target="_blank" rel="noopener noreferrer">
				<i class="fa fa-twitter fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_linkedin fa-stack fa-lg">
				<a href="https://www.linkedin.com/company/mednewstoday" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-linkedin fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_pinterest fa-stack fa-lg">
				<a href="https://www.pinterest.com/search/pins/?q=www.medicalnewstoday.com" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-pinterest fa-stack-1x fa-inverse"></i>
				</a></span>
			</div> 		
			<div id="footer_list">
				<ul>
								<li><a href="/popular" title="View our most popular news articles">Popular news</a></li>
				<li><a href="/archive" title="View all our editorial articles">Editorial articles</a></li>
				<li><a href="/categories" accesskey="m" title="View our complete news category list">All news topics</a></li>
				<li><a href="/knowledge-center" title="Medical conditions and information center">Knowledge center</a></li>

								<li><a href="/newsletter" title="Medical News Today in your inbox">Newsletters</a></li>


					
				<li><a href="/share-our-content" title="Share our content">Share our content</a></li>

								<li><a href="/about" title="About Medical News Today">About us</a></li>
				<li><a href="/authors" title="Our editorial team">Our editorial team</a></li>
				<li><a href="/contact" title="Contact the Medical News Today team">Contact us</a></li>
				<li><a href="/advertising" title="Advertise with Medical News Today">Advertise with MNT</a></li>
				</ul>
			</div> 				
			<span class="footer_separator">
				<span></span>
			</span> 			
			<div id="footer_newsletter">
					<h3 id="footer_newsletter_h3">get our newsletter</h3>
					<span id="footer_newsletter_span">Health tips, wellness advice and more.</span>
					
					<div class="form-group">
						<form method="post" action="#" name="footerNewsletterSignup" id="footerNewsletterSignup" class="newsletterForm">
						<div>
							<input type="text" name="formEmail" id="EmailAddress" class="newsletterFormEmail" placeholder="Enter your email address" size="25" maxlength="150"/>

							<button type="button"
									data-signup-source="footer_newsletter_link"
									class="btn btn-success btn-lg btn-block btn-footer footer_newsletter_link email-signup-btn new_reg_signup">Subscribe</button>

							<div id="footerNewsletterErrorHolder" class="errorHolder"></div>
							

<p>Your <a href="/privacy-policy" title="Privacy policy">privacy</a> is important to us.</p>

						</div>


						</form>

					</div> 				
			</div> 			
			<span class="footer_separator">
				<span></span>
			</span> 			
			<div id="copyright">
				<div class="honcode_img">
				<a href="https://www.healthonnet.org/HONcode/Conduct.html?HONConduct391155" class="seal" onclick="window.open(this.href); return false;">
				<img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://www.honcode.ch/HONcode/Seal/HONConduct391155_s1.gif" alt="This website is certified by Health On the Net Foundation. Click to verify."></a>
				</div> 				<div class="copyright_text float_left">
					<p>Healthline Media UK Ltd, Brighton, UK.</p>
					<p>&copy; 2004-2019 All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.</p>
				</div> 				<div class="copyright_text float_right">
					<p><a href="/privacy-policy" title="View our privacy policy" onclick="fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'New Header - Desktop - Footer', eventAction: 'Footer - Privacy policy', eventLabel: 'Footer - Privacy policy' });});" >Privacy</a> |
					<a href="/terms" title="View our terms of use" onclick="fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'New Header - Desktop - Footer', eventAction: 'Footer - Terms', eventLabel: 'Footer - Terms' });});">Terms</a> |
					<a href="/ad-policy" title="View our advertising policy">Ad policy</a> | 
					<a href="https://www.healthline.com/health/careers" title="Careers" rel="noopener" target="_blank">Careers</a></p>
				</div> 			</div> 			
			<div class="footer_truste_container">
				<div class="footer_truste"><a href="//privacy.truste.com/privacy-seal/validation?rid=b59e7a69-59cd-449f-9af4-2bdba7d346e5" rel="noopener noreferrer" target="_blank"><img style="border: none" src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=b59e7a69-59cd-449f-9af4-2bdba7d346e5" alt="TRUSTe"></a></div>
			</div> 			
		</div> 	
				
	</div> 
</div> 
<footer>

<div id="print_message">
	<p>This page was printed from: <strong><a href="https://www.medicalnewstoday.com/articles/325954.php">https://www.medicalnewstoday.com/articles/325954.php</a></strong></p>
	<p>Visit <strong><a href="https://www.medicalnewstoday.com">www.medicalnewstoday.com</a></strong> for medical news and health news headlines posted throughout the day, every day.</p>
	<hr/>
	<p>2019 Healthline Media UK Ltd. All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.</p>
</div> 



<script type="text/javascript">
		eval(function(p,a,c,k,e,d){e=function(c){return(c<a?'':e(parseInt(c/a)))+((c=c%a)>35?String.fromCharCode(c+29):c.toString(36))};if(!''.replace(/^/,String)){while(c--){d[e(c)]=k[c]||e(c)}k=[function(e){return d[e]}];e=function(){return'\\w+'};c=1};while(c--){if(k[c]){p=p.replace(new RegExp('\\b'+e(c)+'\\b','g'),k[c])}}return p}('3 j=d.1i(\'.A-1p 8\');4(j&&j.c("b-7")){j.7=j.c("b-7");j.1r(\'b-7\')}3 9=[].v.w(d.o(\'8[b-7]\'));3 Q=5(q,g){4(q.g==""){q.g=g}B{3 1d=q.g.1s(" ");4(1d.u(g)==-1){q.g+=" "+g}}};1j(3 i=0;i<9.L;i++){4(9[i].1e.1e.p[0]==\'1n\'){Q(9[i],"A-f")}B{Q(9[i],"f")}}d.m("1t",5(){9=[].v.w(d.o(\'8.A-f\'));9.t(5(2){2.7=2.c("b-7");2.p.D("A-f")});9=[].v.w(d.o(\'8.f\'));3 16=18 6!=="1D";3 13=16&&!("1x"n 6)||/(1w|1y|1z)1E|1A|1H/i.1G(1I.1l);4(13){9.t(5(2){2.7=2.c("b-7");2.p.D("f")})}B{4("V"n 6){4(\'F\'n 6&&\'X\'n 6.F.J&&!(\'O\'n F.J)){1C.1q(6.F.J,\'O\',{1B:5(){1h l.X>0}})}3 G=1F V(5(Y,1v){Y.t(5(S){4(S.O){3 2=S.N;2.p.D("f");2.7=2.c("b-7");M(2);G.1m(2)}})},{1k:"T T 1u T"});9.t(5(2){G.1o(2)})}B{3 y;5 h(){9=[].v.w(d.o(\'.f\'));4(y){1Q(y)}y=2g(5(){3 2k=6.2d;9.t(5(8){4((8.W().27-2c<=6.2l&&8.W().2b>=0)&&2a(8).29!=="26"){8.7=8.c("b-7");8.p.D(\'f\');M(8)}});4(9.L==0){d.U("12",h);6.U("11",h);6.U("10",h)}},20)}h();d.m("12",h);6.m("11",h);6.m("10",h)}5 M(2){2.1J=5(){4(2.c(\'b-I-2-x\')){28(2.c(\'b-I-2-x\'),"",R)}4(2.c(\'b-Z-2-x\')){2e(2.c(\'b-Z-2-x\'),"",1a)}}}}3 K=d.o(\'.2j a:2i(.2h)\');1j(3 E=0;E<K.L;E++){3 C=K[E];4(C.s.u(6.1b.s)===-1&&C.s!=""){C.m("I",5(e){4(e.N.g.u("2-2f")>-1){1h 1f}e.24();3 k=l.s;3 P="17 1g - 25 14 15";3 1c=k;3 H=l.1R;3 z=l.1i("8");4(z){H=z.1S||z.1P}3 r=1f;4(18 k!=="1O"&&k.u("1K.1L")===-1){r=R;P="17 1g - 1M 14 15"}4(l.N==="1N"){r=R}4(r){3 19=6.1T(k);19.1U=1a}21(0,5(){22(\'23\',\'1Z\',{1Y:P,1V:H,1W:1c,1X:5(){4(!r){6.1b.s=k}}})})})}}});',62,146,'||image|var|if|function|window|src|img|lazyloadImages||data|getAttribute|document||lazy|className|lazyload||owlCarouselFirstImage|originHref|this|addEventListener|in|querySelectorAll|classList|element|newWindow|href|forEach|indexOf|slice|call|index|lazyloadThrottleTimeout|imageDom|owl|else|linkDOM|remove|articleIndex|IntersectionObserverEntry|imageObserver|gaAction|click|prototype|linksInArticle|length|includeImagePlugin|target|isIntersecting|gaCategory|addLazyClass|true|entry|0px|removeEventListener|IntersectionObserver|getBoundingClientRect|intersectionRatio|entries|sharing|orientationChange|resize|scroll|isBot|Link|Click|runningOnBrowser|Article|typeof|newWnd|null|location|gaLabel|arr|parentNode|false|Body|return|querySelector|for|rootMargin|userAgent|unobserve|item|observe|carousel|defineProperty|removeAttribute|split|DOMContentLoaded|300px|observer|gle|onscroll|ing|ro|crawl|get|Object|undefined|bot|new|test|spider|navigator|onload|medicalnewstoday|com|Outbound|_blank|undefiend|alt|clearTimeout|innerHTML|title|open|opener|eventAction|eventLabel|hitCallback|eventCategory|event||fireOrSaveJsFunctions|ga|send|preventDefault|Internal|none|top|loadClickableImageByIndex|display|getComputedStyle|bottom|300|pageYOffset|loadImageSharingImageByIndex|clickable|setTimeout|collapsed__click|not|article_body|scrollTop|innerHeight'.split('|'),0,{}))

</script>
<script type="text/javascript">
	window.ga=window.ga||function(){};
	if (typeof window.googletag === 'undefined') {
		//Fallback safe for googletag
    	var googletag = googletag || { };
		googletag.cmd = googletag.cmd || [ ];
	}
	
	//Fallback for Adbridg
	if (typeof window.AdBridg === 'undefined') {
		var AdBridg = AdBridg || {};
  		AdBridg.cmd = AdBridg.cmd || [];
	}

</script>







<script type="text/javascript">



		vanillaAjax("https://pavlov-prod.healthline.com/api/metrics","POST",'{"metrics":[{"type":"increment","name":"ui.pageview"}],"build":"1","route":"php","path":"/articles/325954.php","formfactor":"desktop","site":"mnt","abSegment":""}','{"Content-Type":"text\/plain;charset=UTF-8"}');






</script>


<script type="text/javascript" >
			var is_userMobile=0;
			var is_userTablet=0;
			var glob_responsiveOverride=0;
			var glob_customUserID=0;
			var category=[{"displayNavName":"ADHD \/ ADD","url":"adhd"},{"displayNavName":"Allergy","url":"allergy"},{"displayNavName":"Alzheimer's \/ Dementia","url":"alzheimers"},{"displayNavName":"Anxiety \/ Stress","url":"anxiety"},{"displayNavName":"Rheumatology","url":"rheumatology"},{"displayNavName":"Respiratory","url":"respiratory"},{"displayNavName":"Bipolar","url":"bipolar"},{"displayNavName":"Body Aches","url":"bodyaches"},{"displayNavName":"Breast Cancer","url":"breast_cancer"},{"displayNavName":"Cancer \/ Oncology","url":"cancer-oncology"},{"displayNavName":"Cardiovascular \/ Cardiology","url":"cardiovascular"},{"displayNavName":"Caregivers \/ Homecare","url":"caregivers"},{"displayNavName":"Cholesterol","url":"cholesterol"},{"displayNavName":"Crohn's","url":"crohns"},{"displayNavName":"Cystic Fibrosis","url":"cystic_fibrosis"},{"displayNavName":"Depression","url":"depression"},{"displayNavName":"Dermatology","url":"dermatology"},{"displayNavName":"Diabetes","url":"diabetes"},{"displayNavName":"Erectile Dysfunction","url":"erectile_dysfunction"},{"displayNavName":"Fertility","url":"fertility"},{"displayNavName":"Obesity \/ Weight Loss \/ Fitness","url":"fitness-obesity"},{"displayNavName":"Headache \/ Migraine","url":"headache-migraine"},{"displayNavName":"Liver Disease \/ Hepatitis","url":"liver_disease"},{"displayNavName":"HIV and AIDS","url":"hiv-aids"},{"displayNavName":"Hypertension","url":"hypertension"},{"displayNavName":"Irritable Bowel Syndrome","url":"ibs"},{"displayNavName":"Lung Cancer","url":"lung_cancer"},{"displayNavName":"Lymphoma","url":"lymphoma"},{"displayNavName":"Men's Health","url":"mens_health"},{"displayNavName":"Mental Health","url":"mental_health"},{"displayNavName":"Neurology \/ Neuroscience","url":"neurology"},{"displayNavName":"Pregnancy \/ Obstetrics","url":"pregnancy"},{"displayNavName":"Psychology \/ Psychiatry","url":"psychology-psychiatry"},{"displayNavName":"Schizophrenia","url":"schizophrenia"},{"displayNavName":"Seniors \/ Aging","url":"seniors"},{"displayNavName":"Sexual Health \/ STDs","url":"sexual_health"},{"displayNavName":"Statins","url":"statins"},{"displayNavName":"Urology \/ Nephrology","url":"urology-nephrology"},{"displayNavName":"Women's Health","url":"womens_health"},{"displayNavName":"Pediatrics \/ Children's Health","url":"pediatrics"},{"displayNavName":"Radiology \/ Nuclear Medicine","url":"radiology"},{"displayNavName":"Bones \/ Orthopedics","url":"bones"},{"displayNavName":"Public Health","url":"public_health"},{"displayNavName":"Bio-terrorism \/ Terrorism","url":"bioterrorism"},{"displayNavName":"Aid \/ Disasters","url":"aid-disasters"},{"displayNavName":"Genetics","url":"genetics"},{"displayNavName":"Ear, Nose and Throat","url":"ent"},{"displayNavName":"Alcohol \/ Illegal Drugs","url":"alcohol"},{"displayNavName":"Nursing \/ Midwifery","url":"nursing"},{"displayNavName":"Medical Students \/ Training","url":"medical_students"},{"displayNavName":"Pharma \/ Biotech Industry","url":"pharma_industry"},{"displayNavName":"Stem Cell Research","url":"stem_cell"},{"displayNavName":"Dentistry","url":"dentistry"},{"displayNavName":"Bird Flu \/ Avian Flu","url":"birdflu"},{"displayNavName":"MRSA \/ Drug Resistance","url":"mrsa-superbug"},{"displayNavName":"Eye Health \/ Blindness","url":"eye_health"},{"displayNavName":"Tropical Diseases","url":"tropical_diseases"},{"displayNavName":"Cleft Palate","url":"cleft_palate"},{"displayNavName":"Infectious Diseases","url":"infectious_diseases"},{"displayNavName":"Parkinson's Disease","url":"parkinsons_disease"},{"displayNavName":"GastroIntestinal","url":"gastrointestinal"},{"displayNavName":"CJD \/ vCJD \/ Mad Cow Disease","url":"cjd-vcjd"},{"displayNavName":"Nutrition \/ Diet","url":"nutrition-diet"},{"displayNavName":"Gout","url":"gout"},{"displayNavName":"Stroke","url":"stroke"},{"displayNavName":"Complementary Medicine","url":"complementary_medicine"},{"displayNavName":"Endocrinology","url":"endocrinology"},{"displayNavName":"Biology \/ Biochemistry","url":"biology-biochemistry"},{"displayNavName":"Multiple Sclerosis","url":"multiple_sclerosis"},{"displayNavName":"Autism","url":"autism"},{"displayNavName":"Water - Air Quality \/ Agriculture","url":"water_quality"},{"displayNavName":"Immune System \/ Vaccines","url":"immune_system"},{"displayNavName":"Lupus","url":"lupus"},{"displayNavName":"Cosmetic Medicine","url":"cosmetic_medicine"},{"displayNavName":"Rehabilitation","url":"rehabilitation"},{"displayNavName":"Pain \/ Anesthetics","url":"pain"},{"displayNavName":"Hearing \/ Deafness","url":"hearing-deafness"},{"displayNavName":"Muscular Dystrophy \/ ALS","url":"muscular_dystrophy"},{"displayNavName":"Sports Medicine \/ Fitness","url":"sports_medicine"},{"displayNavName":"MRI \/ PET \/ Ultrasound","url":"mri-pet"},{"displayNavName":"Huntingtons Disease","url":"huntingtons_disease"},{"displayNavName":"Medical Devices \/ Diagnostics","url":"medical_devices"},{"displayNavName":"Smoking \/ Quit Smoking","url":"smoking"},{"displayNavName":"Transplants \/ Organ Donations","url":"transplants"},{"displayNavName":"Sleep \/ Sleep Disorders","url":"sleep"},{"displayNavName":"IT \/ Internet \/ E-mail","url":"it"},{"displayNavName":"Dyslexia","url":"dyslexia"},{"displayNavName":"Medicare \/ Medicaid \/ SCHIP","url":"medicare-medicaid"},{"displayNavName":"Epilepsy","url":"epilepsy"},{"displayNavName":"Prostate \/ Prostate Cancer","url":"prostate"},{"displayNavName":"Veterinary","url":"veterinary"},{"displayNavName":"Abortion","url":"abortion"},{"displayNavName":"Health Insurance","url":"health_insurance"},{"displayNavName":"Litigation","url":"medical_malpractice"},{"displayNavName":"Clinical Trials \/ Drug Trials","url":"clinical_trials"},{"displayNavName":"Conferences","url":"conferences"},{"displayNavName":"Compliance","url":"compliance"},{"displayNavName":"Primary Care \/ General Practice","url":"primary_care"},{"displayNavName":"Flu \/ Cold \/ SARS","url":"flu-sars"},{"displayNavName":"Blood \/ Hematology","url":"blood"},{"displayNavName":"Colorectal Cancer","url":"colorectal_cancer"},{"displayNavName":"Acid Reflux \/ GERD","url":"gerd"},{"displayNavName":"Cervical Cancer \/ HPV Vaccine","url":"cervical_cancer"},{"displayNavName":"Eating Disorders","url":"eatingdisorders"},{"displayNavName":"Pharmacy \/ Pharmacist","url":"pharmacy"},{"displayNavName":"Regulatory Affairs","url":"regulatoryaffairs"},{"displayNavName":"Ovarian Cancer","url":"ovarian_cancer"},{"displayNavName":"Menopause","url":"menopause"},{"displayNavName":"Psoriasis","url":"psoriasis"},{"displayNavName":"Tuberculosis","url":"tuberculosis"},{"displayNavName":"Back Pain","url":"back-pain"},{"displayNavName":"Heart Disease","url":"heart-disease"},{"displayNavName":"Asbestos \/ Mesothelioma","url":"asbestos"},{"displayNavName":"Lymphology \/ Lymphedema","url":"lymphology"},{"displayNavName":"Veterans \/ Ex-Servicemen","url":"veterans"},{"displayNavName":"Medical Practice Management","url":"medical_practice"},{"displayNavName":"Melanoma \/ Skin Cancer","url":"melanoma"},{"displayNavName":"COPD","url":"copd"},{"displayNavName":"Palliative Care \/ Hospice Care","url":"palliative_care"},{"displayNavName":"Vascular","url":"vascular"},{"displayNavName":"Fibromyalgia","url":"fibromyalgia"},{"displayNavName":"Pancreatic Cancer","url":"pancreatic-cancer"},{"displayNavName":"Preventive Medicine","url":"preventive-medicine"},{"displayNavName":"Swine Flu","url":"swine-flu"},{"displayNavName":"Restless Legs Syndrome","url":"restless-legs"},{"displayNavName":"Food Intolerance","url":"food-intolerance"},{"displayNavName":"Personal Monitoring","url":"personal-monitoring"},{"displayNavName":"Surgery","url":"surgery"},{"displayNavName":"Emergency Medicine","url":"emergency-medicine"},{"displayNavName":"Pulmonary System","url":"pulmonary-system"},{"displayNavName":"Medical Innovation","url":"medical-innovation"},{"displayNavName":"Ebola","url":"ebola"},{"displayNavName":"Ulcerative Colitis","url":"ulcerative-colitis"},{"displayNavName":"Constipation","url":"constipation"},{"displayNavName":"Arrhythmia","url":"arrhythmia"},{"displayNavName":"Osteoporosis","url":"osteoporosis"},{"displayNavName":"Diabetes Type 1","url":"diabetes-type-1"},{"displayNavName":"Diabetes Type 2","url":"diabetes-type-2"},{"displayNavName":"Dry Eye","url":"dry-eye"},{"displayNavName":"Endometriosis","url":"endometriosis"},{"displayNavName":"Psoriatic Arthritis","url":"psoriatic-arthritis"},{"displayNavName":"Hypothyroid","url":"hypothyroid"},{"displayNavName":"Shingles","url":"shingles"},{"displayNavName":"Premature Ejaculation","url":"premature-ejaculation"},{"displayNavName":"Asthma","url":"asthma"},{"displayNavName":"VTE","url":"vte"},{"displayNavName":"Seasonal Allergy","url":"seasonal-allergy"},{"displayNavName":"Food Allergy","url":"food-allergy"},{"displayNavName":"OAB","url":"oab"},{"displayNavName":"Urinary Tract Infection","url":"urinary-tract-infection"},{"displayNavName":"Leukemia","url":"leukemia"},{"displayNavName":"Osteoarthritis","url":"osteoarthritis"},{"displayNavName":"Rheumatoid Arthritis","url":"rheumatoid-arthritis"},{"displayNavName":"Birth Control","url":"birth-control-contraception"},{"displayNavName":"Head and Neck Cancer","url":"head-and-neck-cancer"},{"displayNavName":"Atopic Dermatitis","url":"atopic-dermatitis-eczema"},{"displayNavName":"Bites and Stings","url":"bites-stings"}];
			var glob_testServer = 0;
			var resetpw = 0;
			var glob_newSkin = 1;
			var glob_menu_prefix = 'New Header';
			var glob_deviceInfo = 'Desktop';
			var glob_newRegistration = 1;
			var glob_triggerSurvey = 0;
			var glob_pageType = 'article';
			var glob_siteRevision = 7721;
			var showNewsletterPopup = 1;
			var showFocusGroupPopup = 0;
			</script>



							<script type="text/javascript" src="https://cdn-prod.medicalnewstoday.com/structure/javascript/out/mnt_default.js?v=190904" defer></script>
				
		<script src="https://healthline-com.videoplayerhub.com/galleryloader.js" defer></script>

	




<script type="text/javascript">

	fireOrSaveJsFunctions(1,function(){

		var tempAacctTid =setInterval(function() {

			if(typeof _qevents !== "undefined"){
				//wait until _qevents had been set
				_qevents.push( { qacct:"p-v03RmX3GES6RT"} );
				clearInterval(tempAacctTid);
			}

		}, 500);

	});

</script>
<noscript>
	<div style="display: none;">
		<img src="https://pixel.quantserve.com/pixel/p-test123.gif" height="1" width="1" alt="Quantcast"/>
	</div>
</noscript>


<script src="https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/oct.js" type="text/javascript"></script>
<script type="text/javascript">

	fireOrSaveJsFunctions(1,function(){
		twttr.conversion.trackPid('l4bfr');
	});

</script>
<noscript>
	<img height="1" width="1" style="display:none;" alt="" src="https://analytics.twitter.com/i/adsct?txn_id=l4bfr&p_id=Twitter" />
</noscript>



<div id="fb-root"></div>
<script>


	fireOrSaveJsFunctions(1,function(){

		(function(d, s, id) {
  var js, fjs = d.getElementsByTagName(s)[0];
  if (d.getElementById(id)) return;
  js = d.createElement(s); js.id = id;
  js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3&appId=147184211975697";
  fjs.parentNode.insertBefore(js, fjs);
		}(document, 'script', 'facebook-jssdk'));

	});


</script>






<script>
	glob_categoryID="71";glob_categoryName="Multiple Sclerosis category";glob_bindingK1="ms";</script>



<div id="amzn-assoc-ad-c3555b57-ee3e-4ba5-b6f4-ec40911af7e4"></div>
<script>

	fireOrSaveJsFunctions(1,function(){loadScript(
		"//z-na.amazon-adsystem.com/widgets/onejs?MarketPlace=US&adInstanceId=c3555b57-ee3e-4ba5-b6f4-ec40911af7e4",
		{},
		function(){}

	)});

</script>


	<script>
		// 1. create object of script
		var deferCSS = document.createElement('script');
		deferCSS.src = 'https://hello.myfonts.net/count/333229';
		deferCSS.type = 'text/javascript';
		deferCSS.defer = true;

		// 2. declaire position of </body>
		var deferCSS_place = document.getElementsByTagName('body')[0];

		// 3. insert object before </body>
		deferCSS_place.appendChild(deferCSS);
	</script>




<!-- Begin medicalnewstoday.com BlueKai Tag --> 
<script type="text/javascript"> 
window.bk_async = function() { 
	bk_addPageCtx('categoryMain', 'multiple_sclerosis');
	bk_addPageCtx('categorySub', 'pharmacy');
	bk_addPageCtx('dimension28', 'ms');
	bk_addPageCtx('dimension29', 'musculoskeletal');
	BKTAG.doTag(76945, 10);
}; 
(function() { 
	var scripts = document.getElementsByTagName('script')[0]; 
	var s = document.createElement('script'); 
	s.async = true; 
	s.src = "https://tags.bkrtx.com/js/bk-coretag.js"; 
	scripts.parentNode.insertBefore(s, scripts); 
}()); 
</script> 
<!-- End BlueKai Tag --> 




<script type="text/javascript" >
				var articleID="325954";
				var articleType = "drugs";
				var emailID = "325954";
				var articleURL = "/articles/325954.php";
				var threadID = "0";
				var opinionsOutput = 0;
				var showAdsOnArticle = 1;
				var isSponsored = 0;
				</script>
    <script type="text/javascript">
    
		for(var contentBlocksDoms=document.querySelectorAll(".infobox_large.article-tcblocks > li"),i=0;i<contentBlocksDoms.length;i++){var _this=contentBlocksDoms[i],mobileHeadline=_this.querySelector("a  > div.headline.mobile"),excerpt=_this.querySelector("a > div > .excerpt"),desktopHeadlineHtmlStr=mobileHeadline.outerHTML;desktopHeadlineHtmlStr=desktopHeadlineHtmlStr.replace(/(class=\".*?)\s*mobile\s*(.*?\")/g,"$1$2"),null===_this.querySelector("a > div > .headline")&&excerpt.insertAdjacentHTML("beforebegin",desktopHeadlineHtmlStr),_this.getElementsByTagName("a")[0].removeChild(mobileHeadline)}

		//Remove  class hide in tabbed content to show on desktop/ tablet
		if(document.getElementsByClassName("collapsed__tabs")[0]){
			document.getElementsByClassName("collapsed__tabs")[0].classList.remove('hide');	
		}

    </script>



	<script type="text/javascript">

		var articleTOC = document.getElementsByClassName("article_toc")[0];

		if(document.body.contains(articleTOC)){
			// if the page contains article TOC, we do the trick
			var articleTOCpreviousElement = articleTOC.previousElementSibling;

			if(articleTOCpreviousElement){
				if((articleTOCpreviousElement.className.indexOf("photobox_header") !==-1&&articleTOCpreviousElement.querySelector("em") != null)||(articleTOCpreviousElement.className.indexOf("photobox_left") !==-1&&articleTOCpreviousElement.querySelector("em") != null)||(articleTOCpreviousElement.className.indexOf("photobox_right") !==-1&&articleTOCpreviousElement.querySelector("em") != null)){
					articleTOC.classList.add("article_collapsed--top");
				}
			}

		}

	</script>



	<input type="hidden" id="newsid" name="newsid" value="325954">
	<input type="hidden" id="categoryid" name="categoryid" value="71">
	<input type="hidden" id="glob" name="glob" value="0">
	<input type="hidden" id="ratingHCP" name="ratingHCP" value="0">
	<input type="hidden" id="ratingPublic" name="ratingPublic" value="0">
	<input type="hidden" id="alreadyRated" name="alreadyRated" value="0">
	<input type="hidden" id="kcarticle" name="kcarticle" value="0">
	<input type="hidden" id="bottomRatingsBoxReadOnly" name="bottomRatingsBoxReadOnly" value="true">
		
	
				<script type="text/javascript" src="https://cdn-prod.medicalnewstoday.com/structure/javascript/out/mnt_article_7721.js" defer></script>
		

		




<script type="text/javascript">
var mntDataLayer = "";
//Fire in adblock.js cause that's the last event in the page 
function setMNTDataLayer(e) {
	mntDataLayer = {"article_meta":{"publisher":"Medical News Today","headline":"Tecfidera (dimethyl fumarate)","description":"Tecfidera (dimethyl fumarate) is a brand-name prescription drug that's used to treat relapsing forms of multiple sclerosis (MS). It's classified as a disease-modifying therapy. Tecfidera comes as a delayed-release oral capsule. It doesn't have a generic version. Learn about side effects, warnings, dosage, and more.","url":"\/articles\/325954.php","CanonicalURL":"https:\/\/www.medicalnewstoday.com\/articles\/325954.php","datePublished":"2019-08-31","dateUpdated":"","dateReviewed":"2018-09-27","author":"MNT\u2019s Medical Network","coAuthor":"","reviewer":"Lindsay Slowiczek, PharmD","ratingHCP":0,"ratingPublic":0,"commentCount":0,"shareCountFacebook":0,"shareCountGooglePlus":0,"shareCountLinkedIn":0,"shareCountPinterest":0,"ampURL":"","ampVersion":"N"},"reader":{"loggedIn":"no"},"targeting":{"categoryMain":"multiple_sclerosis","categorySub":["pharmacy"],"articleKeywords":"","articleID":"325954","articleType":"drugs","micrositeID":"tecfideracdi","articleVersion":"v2","articleAge":"week"},"customDimensions":{"siteVersion":"desktop","webServer":-1,"iosAppTraffic":-1,"viewportWidth":0,"viewportHeight":0,"hidpi":0,"adblockStatus":0}}
	mntDataLayer["article_meta"]["shareCountFacebook"] 	 = facebookCount;
	mntDataLayer["article_meta"]["shareCountGooglePlus"] = googlePlusCount;
	mntDataLayer["article_meta"]["shareCountLinkedIn"] 	 = linkedinCount;
	mntDataLayer["article_meta"]["shareCountPinterest"]	 = pinterestCount;
	mntDataLayer["article_meta"]["url"]	 				 = window.location.href;
	mntDataLayer["customDimensions"]["adblockStatus"] 	 = adBlockValue;
 	mntDataLayer["customDimensions"]["viewportWidth"] = Math.max(document.documentElement.clientWidth, window.innerWidth || 0);
 	mntDataLayer["customDimensions"]["viewportHeight"] = Math.max(document.documentElement.clientHeight, window.innerHeight || 0);
 	mntDataLayer["customDimensions"]["hidpi"] = (window.devicePixelRatio >= 1.5) ? "HiDPI" : "1X";
}
</script>

					
			
</div> </body>
</html>
